Visiongain Launches Report Examining the Potential in the $118bn Translational Regenerative Medicine Market – PR Newswire UK

- Translational Regenerative Medicine Market Forecast 2020-2030

- Stem Cell Therapies, Tissue Engineered Products, Gene Therapies

LONDON, March 6, 2020 /PRNewswire/ -- The Global Translational Regenerative Medicine market is estimated to grow at a CAGR of 24% in the first half of the forecast period. Stem cell therapies accounted for the majority of the revenue in the market with an estimated market share of 59% in 2019.

How this report will benefit youRead on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand-new report you will find338-page reportand you will receive116 tables, 104 figures and 3 interviews all unavailable elsewhere.

The 338-page Visiongain report provides clear detailed insight into the Global Translational Regenerative Medicine market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.comor refer to our website: https://www.visiongain.com/report/translational-regenerative-medicine-market-forecast-2020-2030/#download_sampe_div

Report Scope

Global Translational Regenerative Medicine market forecastsfrom 2020-2030

Global Translational Regenerative Medicinesubmarket forecastsfrom 2020-2030 covering: Stem Cell Therapies Tissue Engineered Products Gene Therapies

This study discusses thelate-stage clinical trialsandpipelineas well asmarket driversandrestraintsof each submarket.

Translational Regenerative Medicineregional and nationalmarket forecastsfrom 2020-2030, covering: North America:US, Canada Europe:Germany, France, UK, Italy, Spain, Rest of Europe Asia-Pacific:China, Japan, India, Rest of Asia-Pacific Latin America:Brazil, Mexico, Rest of Latin America Middle East & Africa:GCC Countries, South Africa, Rest of Middle East & Africa

Each regional market is further segmented by sector.

Forecasts from 2020-2030 of the selectedleading productsin the Global Translational Regenerative Medicine market: Osteocel Plus Trinity ELITE TEMCELL /Prochymal Apligraf Dermagraft Epifix ReCell Neovasculgen IMLYGIC (talimogene laherparepvec)

Assessment of theleading companiesin the Global Translational Regenerative Medicine market: Astellas Pharma Athersys Avita Medical AxoGen, Inc. MEDIPOST Co., Ltd. NuVasive Organogenesis Holdings, Inc. Osiris Therapeutics, Inc. Pharmicell Co., Ltd. Takeda uniQure N.V. Vericell Corporation

Information oncurrent developments, current advancementsandcurrent key approvalsin the field of translational regenerative medicine market.

SWOTandPorter's Five Force analysisof the translational regenerative medicine market

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.comor refer to our website: https://www.visiongain.com/report/translational-regenerative-medicine-market-forecast-2020-2030/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.comto discuss any customized research needs you may have.

Companies covered in the report include:

Aastrom Biosciences, Inc.Abeona Therapeutics Inc.AdvantageneAgeless Regenerative InstituteAlliqua BioMedical, Inc.AlloSourceAlphaTecSpineAltrikaAndalusian Initiative for Advanced Therapies - Fundacin Pblica Andaluza Progreso y SaludAnGes MG/VicalAnterogenArizona Pain SpecialistsAssistance Publique Hopitaux De MarseilleAstellas PharmaAthersys, Inc.Avita MedicalAxiogenesis AGAxoGen, Inc.BaxterBellicum PharmaceuticalsBenda PharmaceuticalBiedermann Technologies GmbH & Co. KGBioCardia, Inc.Bioheartbluebird bioBrainStorm Cell TherapeuticsBristol-Meyers SquibbCaladrius BiosciencesCapricorCardio3 BioSciencesCelgeneCell MedicaCellerant TherapeuticsCellular Dynamics International, Inc.CeregeneChiesi Farmaceutici SpACold GenesysCytori TherapeuticsDePuy MitekDimension Therapeutics, Inc.Fibrocell ScienceFUJIFILM CorporationGE HealthcareGenzymeHealeon Medical IncHEALIOS K.K.HemostemixHoffmann-La RocheHomology Medicines, Inc.Innovative Cellular Therapeutics (ICT)Integra LifeSciencesIntrexonInvetechIrvine ScientificJapan Regenerative Medicine Co., Ltd.Japan Tissue Engineering Co. LtdJCR Pharmaceuticals Co. Ltd.Jianwu DaiJohnson & JohnsonKinetic Concepts IncKite PharmaLonza Houston, Inc.MacroCureMedipostMediStemMedtronicMesoblast, Ltd.MidCap Financial Services (MidCap Financial)MiMedx Group, Inc.Nasser Aghdami MD., PhDNovartisNuVasiveOcata TherapeuticsOhioHealthOrchard TherapeuticsOrganogenesis Holdings Inc.OrthofixOsiris Therapeutics, Inc.Oxford BioMedicaPall CorporationParcell LaboratoriesPfizer, Inc.PharmaceuticalPharmicell Co., Ltd.Promethera Biosciences SARegen Lab SARegenerative Patch Technologies, LLCRegenerative Sciences, LLCRegenerys Ltd.RegeneusReNeuronRoyan InstituteSangamo BioSciencesSanofiSemma TherapeuticsServierShanghai SunwayShinya YamanakaSiemens HealthineersSilicon Valley BankSkye OrthobiologicsSobi PartnersSotex PharmFirmSpark TherapeuticsStemCells Inc.Stempeutics ResearchTakeda PharmaceuticalsTiGenixTissueGene, Inc.U.S. Stem Cell Inc.uniQure NVUniversal Cells, Inc.Vericell CorporationViaCyte IncXenetic BiosciencesZimmer

List of Organisations Mentioned in This ReportAcademy Military Medical Science, ChinaAmerican Diabetes AssociationAndalusian Initiative for Advanced TherapiesArthritis Research UKAustralian Regenerative Medicine InstituteAustralian Research CouncilBanc de Sang i TeixitsBeijing Cancer HospitalBrazil Ministry of Health, Ministry of EducationBrazilian Development Bank (BNDES)British Heart FoundationCambridge University Hospitals NHS Foundation TrustCatalan Institution for Research and Advanced StudiesCenter for Biologics Evaluation and Research (CBER)Center for Devices and Radiological Health (CDRH).Center for Drug Evaluation and Research (CDER)Centre Hospitalier Ren DubosCharit University ClinicChina Construction bankChinese Academy of SciencesCommittee for Advanced TherapiesCommittee for Medicinal Products for Human Use (CHMP)Department of Health and the Care Quality CommissionDrugs Controller General of IndiaEuropean CommissionEuropean Group for Blood and Marrow TransplantationEuropean Medicines AgencyEuropean Patent OfficeEuropean UnionFood and Drug Administration (FDA)Fourth Military Medical UniversityGerman National Registry of Blood Stem Cell DonorsHerlev HospitalHouse of Lords Science and Technology CommitteeHuman Fertilisation and Embryology AuthorityHuman Stem Cell InstituteInnovation in JapanInstitute for Biomedical ResearchKenneth HargreavesKing Abdullah International Medical Research Centre (KAIMRC)King Khaled UniversityKing Saud bin Abdulaziz University for Health Sciences (KSAU - HS)Korea Food and Drug AdministrationKuopio University HospitalMassachusetts General Hospital (MGH)Medical Research CouncilMinistry of Food and Drug SafetyMinistry of Public Health, Republic of BelarusMusculoskeletal Transplant Foundation (MTF)Northwestern UniversityNursing Association for the Study of Cutaneous WoundsOregon Health and Science UniversityPharmaceuticals and Medical Devices Agency (PMDA)Regenerative Medicines in Europe Project (REMEDiE)Russian Academy of Medical SciencesRussian Ministry of Healthcare and Social DevelopmentServizio Sanitario Nazionale, ItalySidney Kimmel Comprehensive Cancer CenterSouth African GovernmentSouth China Research Center for Stem Cell and Regenerative MedicineStanford UniversityState Food and Drug AdministrationThe University of Texas Health Science Center, HoustonTherapeutics Goods AdministrationUniversity College LondonUniversity Hospital of Basel, SwitzerlandUniversity of California, Los Angeles (UCLA)University of California, San Francisco (UCSF)University of LeedsUniversity of MassachusettsWenzhou Medical UniversityWorld BankYamaguchi University Hospital

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Related reports:

Global Stem Cell Technologies and Applications Market 2019-2029

Biobanking Market Forecasts 2019-2029

Global Precision Medicine Market Forecast 2019-2029

Global Rare Disease Drugs Market Forecast 2019-2029

Global Bioreactors Market 2020-2030

Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg

SOURCE Visiongain

See the rest here:
Visiongain Launches Report Examining the Potential in the $118bn Translational Regenerative Medicine Market - PR Newswire UK

Scorpion Venom Used to Direct T Cells to Target Brain Cancer Tumors – SciTechDaily

Blue indicates the cell nuclei (big: tumor cell; small: T cell). The aggregation of yellow color at the interface between the two cells is the formation of immune synapse, a key indicator of T cell activation which will lead to tumor killing. Credit: City of Hope

The research published today, and scorpion venom will also be key component of CAR T cell therapy for glioblastoma in newly opened City of Hope clinical trial.

City of Hope scientists have developed and tested the first chimeric antigen receptor (CAR) T cell therapy using chlorotoxin (CLTX), a component of scorpion venom, to direct T cells to target brain tumor cells, according to a preclinical study published today (March 4, 2020) in Science Translational Medicine. The institution has also opened the first in-human clinical trial to use the therapy.

CARs commonly incorporate a monoclonal antibody sequence in their targeting domain, enabling CAR T cells to recognize antigens and kill tumor cells. In contrast, the CLTX-CAR uses a 36-amino acid peptide sequence first isolated from death stalker scorpion venom and now engineered to serve as the CAR recognition domain.

Glioblastoma (GBM), the most common type of brain tumor, is also among the most deadly of human cancers, according to the American Cancer Society. It is particularly difficult to treat because the tumors are disseminated throughout the brain. Efforts to develop immunotherapies, including CAR T cells, for GBM must also contend with a high degree of heterogeneity within these tumors.

For the study, City of Hope researchers used tumor cells in resection samples from a cohort of patients with GBM to compare CLTX binding with expression of antigens currently under investigation as CAR T cell targets, including IL13R2, HER2 and EGFR. They found that CLTX bound to a greater proportion of patient tumors, and cells within these tumors.

CLTX binding included the GBM stem-like cells thought to seed tumor recurrence. Consistent with these observations, CLTX-CAR T cells recognized and killed broad populations of GBM cells while ignoring nontumor cells in the brain and other organs. The study team demonstrated that CLTX-directed CAR T cells are highly effective at selectively killing human GBM cells in cell-based assays and in animal models without off-tumor targeting and toxicity.

Our chlorotoxin-incorporating CAR expands the populations of solid tumors potentially targeted by CAR T cell therapy, which is particularly needed for patients with cancers that are difficult to treat such as glioblastoma, saidChristine Brown, Ph.D., City of Hopes Heritage Provider Network Professor in Immunotherapy and deputy director of T Cell Therapeutics Research Laboratory. This is a completely new targeting strategy for CAR T therapy with CARs incorporating a recognition structure different from other CARs.

Michael Barish, Ph.D., City of Hope professor and chair of the Department of Developmental and Stem Cell Biology, initiated the development of a CAR using chlorotoxin to target GBM cells. The peptide has been used as an imaging agent to guide GBM resection surgery, and to carry radioisotopes and other therapeutics to GBM tumors.

Much like a scorpion uses toxin components of its venom to target and kill its prey, were using chlorotoxin to direct the T cells to target the tumor cells with the added advantage that the CLTX-CAR T cells are mobile and actively surveilling the brain looking for appropriate targets, Barish said. We are not actually injecting a toxin, but exploiting CLTXs binding properties in the design of the CAR. The idea was to develop a CAR that would target T cells to a wider variety of GBM tumor cells than the other antibody-based CARs.

The notion is that the higher the proportion of tumor cells that one can kill at the beginning of treatment, the greater the probability of slowing down or stopping GBM growth and recurrence, Barish added.

Dongrui Wang, a doctoral candidate in City of Hopes Irell & Manella Graduate School of Biological Sciences, was the lead scientist to establish and optimize the CLTX-CAR T cell platform and to determine that cell surface protein matrix metalloprotease 2 is required for CLTX-CAR T cell activation. He added that while people might think the chlorotoxin is what kills the GBM cells, what actually eradicates them is the tumor-specific binding and activation of the CAR T cells.

Based on the promising findings of this study, the study team intends to bring this therapy to patients diagnosed with GBM with the hope of improving outcomes against this thus far intractable cancer. With recently granted Food and Drug Administration approval to proceed, the first-in-human clinical trial using the CLTX-CAR T cells is now screening potential patients.

Reference: Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma by Dongrui Wang, Renate Starr, Wen-Chung Chang, Brenda Aguilar, Darya Alizadeh, Sarah L. Wright, Xin Yang, Alfonso Brito, Aniee Sarkissian, Julie R. Ostberg, Li Li, Yanhong Shi, Margarita Gutova, Karen Aboody, Behnam Badie, Stephen J. Forman, Michael E. Barish3 and Christine E. Brown, 4 March 2020, Science Translational Medicine.DOI: 10.1126/scitranslmed.aaw2672

This work was supported by the Ben & Catherine Ivy Foundation of Scottsdale, Arizona, and the clinical trial will be supported by The Marcus Foundation of Atlanta.

City of Hope, a recognized leader in CAR T cell therapies for glioblastoma and other cancers, has treated nearly 500 patients since its CAR T program started in the late 1990s. The institution continues to have one of the most comprehensive CAR T cell clinical research programs in the world it currently has 29 ongoing CAR T clinical trials, including CAR T trials for HER-2 positive breast cancer that has spread to the brain, and metastatic prostate cancer in the bones. It was the first and only cancer center to treat GBM patients with CAR T cells targeting IL13R2, and the first to administer CAR T cell therapy locally in the brain, either by direct injection at the tumor site, through intraventricular infusion into the cerebrospinal fluid, or both. In late 2019, City of Hope opened a first-in-human clinical trial for patients with recurrent glioblastoma combining IL13R2-CAR T cells with checkpoint inhibitors nivolumab, an anti-PD1 antibody, and ipilimumab, blocking the CTLA-4 protein.

Read more:
Scorpion Venom Used to Direct T Cells to Target Brain Cancer Tumors - SciTechDaily

Bruker Receives Notification from Nasdaq Related to Delayed Annual Report on Form 10-K – Yahoo Finance

Bruker Corporation (Nasdaq: BRKR) today announced that it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, as a result of Brukers delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (the "Form 10-K"), Bruker is not in compliance with the timely filing requirement for continued listing under Nasdaq Listing Rule 5250(c)(1). The notification letter has no immediate effect on the listing or trading of Brukers common stock on the Nasdaq Global Select Market.

Bruker filed a Notification of Late Filing on Form 12b-25 on March 3, 2020, indicating that the filing of the Form 10-K would be delayed pending completion of an internal investigation into an allegation recently received in connection with Brukers year-end close, primarily relating to income tax matters including the effective income tax rate for 2019 and the related income tax balance sheet accounts.

Nasdaq has informed Bruker that it must submit a plan of compliance (the "Plan") within 60 calendar days of receipt of the letter, or no later than May 4, 2020, addressing how it intends to regain compliance with Nasdaqs listing rules and, if Nasdaq accepts the Plan, it may grant an extension of up to 180 calendar days from the Form 10-K original filing due date, or until August 31, 2020, to regain compliance.

Bruker is working diligently and intends to file the Form 10-K as promptly as reasonably practicable after the conclusion of the investigation and within the 60-day period described above, which would eliminate the need for Bruker to submit a formal plan to regain compliance.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Brukers high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. For more information, please visit: http://www.bruker.com.

Forward Looking Statements

Any statements contained in this press release which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the expected timing for the filing of the Form 10-K, the Companys ability to regain compliance with the Nasdaq requirements for continued listing and related matters. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, risks and uncertainties relating to the outcome of the previously announced internal investigation, the failure of the Company to file the Form 10-K on its expected timeline and, and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2018. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200305005878/en/

Contacts

Miroslava MinkovaDirector, Investor Relations & Corporate DevelopmentBruker CorporationT: +1 (978) 6633660, ext. 1479E: Investor.Relations@bruker.com

Go here to see the original:
Bruker Receives Notification from Nasdaq Related to Delayed Annual Report on Form 10-K - Yahoo Finance

Molecular Signature of Young-Onset Parkinson’s Disease Is… : Neurology Today – LWW Journals

Article In Brief

A unique molecular structureevident in induced pluripotent stem cells taken from people with young-onset Parkinson's diseasesuggests that the defects may be present throughout patients' lives, and that they could therefore be used as diagnostic markers.

Induced pluripotent stem cells (iPSCs) taken from patients with young-onset Parkinson's disease (YOPD) and grown into dopamine-producing neurons displayed a molecular signature that was corrected in vitro, as well as in the mice striatum, by a drug already approved by the US Food and Drug Administration (FDA), a study published in the January 27 online edition of Nature Medicine found.

Although the patients had no known genetic mutations associated with PD, the neurons grown from their iPSCs nonetheless displayed abnormally high levels of soluble alpha-synucleina classic phenotype of the disease, but one never before seen in iPSCs from patients whose disease developed later in life. Surprisingly, for reasons not yet understood, the cells also had high levels of phosphorylated protein kinase C-alpha (PKC).

In addition, the cells also had another well-known hallmark of PD: abnormally low levels of lysosomal membrane proteins, such as LAMP1. Because lysosomes break down excess proteins like alpha-synuclein, their reduced levels in PD have long been regarded as a key pathogenic mechanism.

When the study team tested agents known to activate lysosomal function, they found that a drug previously approved by the FDA as an ointment for treating precancerous lesions, PEP005, corrected all the observed abnormalities in vitro: it reduced alpha-synuclein and PKC levels while increasing LAMP1 abundance. It also decreased alpha-synuclein production when delivered to the mouse striatum.

Unexpectedly, however, PEP005 did not work by activating lysosomal function; rather, it caused another key protein-clearing cellular structure, the proteasome, to break down alpha-synuclein more readily.

The findings suggest that the defects seen in the iPSCs are present throughout patients' lives, and that they could therefore be used as diagnostic markers. Moreover, the drug PEP005 should be considered a potentially promising therapeutic candidate for YOPD and perhaps even for the 90 percent of PD patients in whom the disease develops after the age of 50, according to the study's senior author, Clive Svendsen, PhD, director of the Cedars-Sinai Board of Governors Regenerative Medicine Institute and professor of biomedical sciences and medicine at Cedars-Sinai.

These findings suggest that one day we may be able to detect and take early action to prevent this disease in at-risk individuals, said study coauthor Michele Tagliati, MD, FAAN, director of the movement disorders program and professor of neurology at Cedars-Sinai Medical Center.

But the study still raises questions regarding the biological mechanisms, and certainly does not warrant off-label prescribing of PEP005 at this time, said Marco Baptista, PhD, vice president of research programs at the Michael J. Fox Foundation, who was not involved with the study.

Repurposing PEP005 is a long way away, Dr. Baptista said. This is not something that neurologists should be thinking about prescribing or recommending to their patients.

Accumulation of alpha-synuclein has been seen in iPSC-derived dopaminergic cultures taken from patients with known genetic defects, but such defects account for only about 10 percent of the PD population. In those without known mutations, on the other hand, no defects in iPSC-derived dopamine-producing neurons have been seen. Until now, however, such studies had been conducted only in patients who had developed PD after age 50.

My idea was why to look in young-onset patients, said Dr. Svendsen.

The idea paid off more richly than he expected. We were shocked to find a very, very prominent phenotype, a buildup of alpha-synuclein, in the neurons of these patients who are genetically normal, Dr. Svendsen said. None of the controls had a buildup of synuclein, and all but one of the early PD patients had a twofold increase in it.

The signature is so consistent, he said, that it offers a natural model that can be interrogated to further understand its workings.

Because high levels of PKC were also seen, Dr. Svendsen said, We picked a bunch of drugs known to reduce PKC. We found one, PEP005, which is actually extracted from the milkweed plant, and it completely reduced synuclein levels almost to normal in dopaminergic neurons. And it also increased dopamine levels in those cells, so we got two for one.

After observing the effects of PEP005 in vitro, We put it into the mouse brain and found it reduced synuclein in vivo, Dr. Svendsen said. But we had to infuse it right into the brain. We're now trying to work out how to get it across the blood-brain barrier more efficiently.

To determine how PEP005 lowers cellular levels of alpha-synuclein, his group tested whether it was activating the lysosome, but found to their surprise that it did not do this until after the synuclein had already been degraded.

Then we asked whether it could be the proteosome, which also breaks down proteins but normally doesn't break down synuclein, Dr. Svendsen said. But when we applied PEP005, it did activate the proteasome. So we think that might be the mechanism.

Because the drug is currently applied externally, Dr. Svendsen said, the next step will be to see if it crosses the blood-brain barrier when applied to the skin of mice, and whether that results in a lowering of synuclein levels in dopaminergic neurons.

Justin Ichida, PhD, the Richard N. Merkin assistant professor of stem cell biology and regenerative medicine at the USC Keck School of Medicine, said the findings are quite important in the field. The potential diagnostic tools they made could be important in clinical care. And identifying a drug that may very effectively reverse the disease in neurons is a very important discovery.

He wondered, however, whether the increase in alpha-synuclein is truly specific to Parkinson's neurons or if it would also be seen in iPSC neurons from patients with Alzheimer's disease or amyotrophic lateral sclerosis.

I wonder if alpha-synuclein accumulating is a sign of PD in a dish or is a consequence of neurodegeneration or impaired protein degradation in general, Dr. Ichida said. That's a key question if you want to use this molecular signature as a diagnostic tool.

He also questioned if proteins other than alpha-synuclein, such as tau, would also be seen to accumulate in the iPSCs of YOPD patients.

If one of the protein-clearance mechanisms in the cell is working poorly, you would imagine that other things would also accumulate, Dr. Ichida said.

In response, Dr. Svendsen said that while some proteins other than alpha-synuclein were reported in the paper at increased levels, We did not look at tau specifically, but are in the process of looking right now. It could be that synuclein and some other proteins are somehow altered to evade them from being degraded by the lysosome, or that there is a general lysosomal problem.

Patrik Brundin, MD, PhD, director of the Center for Neurodegenerative Science and Jay Van Andel Endowed Chair at Van Andel Research Institute in Grand Rapids, MI, called the paper very interesting and thought-provoking. If these findings hold up, they could shift our understanding of young-onset PD. They imply that there is a strong genetic component that has not been picked up in prior genetic studies.

Dr. Brundin said he would like to see the results replicated in another lab using different sets of reagents. It is so intriguing and rather unexpected that one wonders if the observations really apply, as the study states, to 95 percent of all YOPD.

He also questioned whether all the young-onset PD patients are similar. Clearly the iPSCs studied here are not monogenetic PD, so they must be very diverse genetically and still all have the same alpha-synuclein change.

Dr. Brundin also asked why the abnormalities seen in YOPD neurons have not previously been seen in older cases of PD. Is there a specific cutoff regarding age-of-onset when these purposed genetic differences apply? he asked.

Dr. Svendsen responded: We don't know why the YO have this phenotype or exactly what the cut off is. We have, however, looked at one adult-onset case that did not show this phenotype. Also, one of our YO cases did not show this phenotype. Thus some patients even with early onset may not have it. We are currently testing many more cases from older-onset patients.

Dr. Brundin also wanted to know whether non-dopaminergic neurons have the same deficits described in the study.

We don't know which neurons specifically have the protein deficit as we cannot do single-cell proteomics, Dr. Svendsen answered. It could be a little in all cells or a lot in a small set. Immunocytochemistry is not quantitative but showed that it is more likely a general increase in synuclein and not specific to dopaminergic neurons.

While the findings in iPSCs suggest that the abnormal levels of alpha-synuclein must be present at birth, Dr. Brundin said, I do not know how to reconcile the present findings with genetic data.

The absence of previously described mutations in the YOPD patients means only that more work must be done to uncover the genetic underpinnings, Dr. Svendsen said.

We're just at the tip of the iceberg with understanding the genome, he said. It's such a bizarrely complex beast. Perhaps there are a thousand different proteins interacting to stop the synuclein from being degraded. In 10 years, we probably will be clever enough to see it. We know it must be there. Now the genome guys will go after it.

Dr. Baptista from the Michael J. Fox Foundation said he agreed with the view that there must be genetic alterations underpinning the defects seen in the iPSCs.

Just because we call something non-genetic could simply reflect the current ignorance of the field, he said. I think the discoveries are simply difficult to make.

He added that he wished that the main comparator in the study was not healthy controls, and that there were more older-onset iPSCs to compare against YOPD patients' samples.

Dr. Svendsen said it could be that the iPSCs from older-onset patients might yet be found with additional study to display abnormalities similar to those seen in YOPD.

Right now we only see it in young onset, he said. We may need to leave the cultures longer to see in the older-onset patients. We are doing those experiments now.

Drs. Tagliati and Svendsen disclosed that an intellectual patent is pending for diagnostic and drug screening for molecular signatures of early-onset Parkinson's disease. Dr. Ikeda is a co-founder of AcuraStem Inc. Dr. Brundin has received commercial support as a consultant from Renovo Neural, Inc., Lundbeck A/S, AbbVie, Fujifilm-Cellular Dynamics International, Axial Biotherapeutics, and Living Cell Technologies. He has also received commercial support for research from Lundbeck A/S and Roche and has ownership interests in Acousort AB and Axial Biotherapeutics. Dr. Baptista had no disclosures.

More:
Molecular Signature of Young-Onset Parkinson's Disease Is... : Neurology Today - LWW Journals

Service Center staff encourages students to perform random acts of kindness throughout the week – Ke Alakai

Photo by Keyu Xiao

From writing a kind person's name on the sidewalk with chalk to sharing a genuine smile or an appreciation message to their friends, BYUHawaii students said they participated in the Random Acts of Kindness Week by looking outward and serving others by small and simple means. Students shared thoughts and feelings of happiness by being both the giver and the receiver of these acts.

The Service Center hosted activities to inspire students to perform acts of kindness, said Danilo Mantilla, a senior from Colombia majoring in marketing.

A booth outside of the Joseph F. Smith Library was set up on Feb. 8 where students could write with chalk on the ground about someone who had been kind to them, take a picture, and then send it to the person. Different groups participated, including tours of Japanese students. Students spent time writing one or more names. Mantilla expressed, If we reminded ourselves of how grateful we are for people, the list would be endless, but the chalk wasnt.

Alyssa Allen, a senior from Colorado majoring in humanities, commented, [Random Acts of Kindness] is a national event that happens every year," but she thought "it is the first time BYUHawaii has done it.

Mantilla shared an experience when a friend randomly reached out to him. That feeling of somebody doing something kind for me without me asking ... or without me being present, [it was] something I had never experienced.

The giver

Mahori Eteru, a sophomore from Australia majoring in communications and psychology, said he enjoyed the activity because it lit my day. It is so easy to compare ourselves to others, looking at grades or looking at people next to us, but we looked at people who bless our lives.

He described the way he felt as, All my stress was alleviated, and it cleared my mind ... It made me so happy. I wanted to keep going.

Darby Riley, a sophomore from Utah majoring in molecular and cell biology, said she made the effort during the week to smile at everyone she saw and reach out to those she didnt know. She said, Its easy to do something good for somebody you know, but to do something kind for somebody you dont know takes a step out of the comfort zone. It reminds me of how the Savior works. He didnt just help people He knew, but He was kind to everyone.

It doesnt take a lot of time. I find I am less stressed [when I serve], and I have enough time to get everything I need done. I feel better.

Mantilla shared, Once you get into the world of service, your mind shifts into something else. You forget about yourself and think of others.

Mark Maslar, a sophomore from California majoring in theater education, said, If you invest in doing something kind or remembering something someone else did, then you feel that nice, tender feeling inside and feel it was worth [it].

The receiver

Eteru shared he had his name written down by someone else for being kind. It encouraged me to remember Im doing better than I think Im doing. It feels nice to be appreciated and it was a unique way to do it, said Eteru.

Riley said she had her name written down a total of five times. She shared, I dont think Im the kindest person. I think the people who are usually the most outgoing ... often have an inner struggle with themselves, so it is nice to see [acknowledgment] one in a while.

Sometimes we can beat up ourselves, and we can feel like we're not doing enough. Then, when other people reach out and say, Youre so kind, or Thank you for being there for me, It makes me feel better and [I think], Im doing okay. Im not perfect, but at least I made somebody smile.

Sister Kim Olsen, a senior missionary serving in the Leadership Office with her husband, said, I saw a student folding butterfly origami. They then showed up on the Random Acts of Kindness table outside the Service Center. It is stuff like that, that makes people smile.

Service beyond Random Acts of Kindness Week

Allen said she hopes its something the students can hold onto in their hearts, not just for a week, but a whole year. I hope to build awareness of kindness. I feel kindness goes beyond just our actions. Its also our thoughts and hearts. That would be mission accomplished.

For more information on local service opportunities, visit the Service Center or go online to justserve.org.

Read more:
Service Center staff encourages students to perform random acts of kindness throughout the week - Ke Alakai

Edited Transcript of NKTR earnings conference call or presentation 27-Feb-20 10:00pm GMT – Yahoo Finance

SAN FRANCISCO Mar 6, 2020 (Thomson StreetEvents) -- Edited Transcript of Nektar Therapeutics earnings conference call or presentation Thursday, February 27, 2020 at 10:00:00pm GMT

* Gilbert M. Labrucherie

* Howard W. Robin

Oppenheimer & Co. Inc., Research Division - Executive Director & Senior Analyst

Ladies and gentlemen, thank you for standing by, and welcome to the Nektar Therapeutics Fourth Quarter 2019 Financial Results Conference. (Operator Instructions) Please be advised that today's conference is being recorded.

(Operator Instructions) I would now like to hand the conference over to your speaker today, Ms. Jennifer Ruddock, Head of Corporate Affairs. Ma'am, you may begin.

Thank you, Crystal. Good afternoon, everyone, and thank you for joining us today. With us are Howard Robin, our President and CEO; Gil Labrucherie, our COO and CFO; Dr. Jonathan Zalevsky, our Head of R&D; and Dr. Wei Lin, our Head of Development.

On today's call, we expect to make forward-looking statements regarding our business, including clinical trial results, timing and plans for future clinical trials, timing and plans for future clinical data presentations at medical meetings, the therapeutic potential of our drug candidates, outcomes and plans for health authority regulatory actions and decisions, financial guidance and certain other statements regarding the future of our business. Because these statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict and many of which are outside of our control.

Important risks and uncertainties are set forth in our Form 10-Q that we filed on November 7, 2019, which is available at sec.gov.

We undertake no obligation to update any of these statements, whether as a result of new information, future developments or otherwise. A webcast of this call will be available on the IR page at Nektar's website at nektar.com.

With that, I will now hand the call over to our President and CEO, Howard Robin. Howard?

Howard W. Robin, Nektar Therapeutics - CEO, President & Director [3]

Thank you, Jennifer, and thank you to everyone for joining us on the call today. On today's call, we will provide an update on our pipeline compounds, which include our I-O pipeline of Nektar IL-2, IL-15 and TLR agonist candidates and our immunology program NKTR-358. We will also review our planned upcoming milestones for these programs and provide our financial guidance for 2020. But before I discuss the advancements we made with our I-O and immunology portfolio, I'd like to briefly cover some challenges we faced this year that are outside of the core focus of our pipeline.

Starting with NKTR-181. As you know, we made a strategic decision last month to withdraw the NDA for NKTR-181. The NKTR-181 ADCOM was the first of several that week that were negative for the opioid class, and it became clear from these discussions that the bar for approval of any opioid compound is much higher than what was established by approvals in the past.

Additionally, since that time that we submitted our NDA, the liability in the opioid class has become a significant consideration, with numerous lawsuits filed against opioid manufacturers and distributors. And based upon all of these factors, we made a business decision that further investment could not be justified for a medicine in this class, which would have been at the expense of sacrificing important developmental work for our immuno-oncology pipeline. As we look back at our successful development efforts for this program, I want to thank our team for their hard work, thank the patients and physicians who participated in our clinical trials, some of whom came to speak at the ADCOM. We did not take this decision lightly, but believe it is the appropriate action to take as we focus on the advancement of our I-O and immunology pipeline.

Secondly, as you know, we were conducting the ATTAIN study for our chemotherapy agent, ONZEALD, in advanced breast cancer patients who also have brain metastases, which compared ONZEALD to a chemo agent of choice in these patients.

The ATTAIN study was being partially funded from a former partnership we had with Daiichi Sankyo. And you'll recall that the ATTAIN study was designed based upon a doubling of survival that we saw in a subset of patients from the earlier BEACON study of ONZEALD in advanced breast cancer patients with brain mets as compared to chemotherapy of physician's choice.

The primary analysis of the ATTAIN study was completed late last week. And while ONZEALD performed at least as well as the physician's choice standard of care for PFS and OS, the study endpoint of improvement in overall survival was not met. As a result, we're planning no further clinical work on ONZEALD, and we're grateful to the patients and their families who participated in the ATTAIN study.

With these actions behind us, our company is highly focused in the core areas of immuno-oncology and immunology, where we believe we have the potential to create transformative medicines for patients. Our I-O portfolio is highly differentiated with 2 strong cytokine programs, IL-2 with bempeg and IL-15 with NTKR-255 and a small molecule TLR agonist program. This unique portfolio allows us to capture opportunities that span both solid and liquid tumors. In immunology, NKTR-358 is advancing into several clinical studies in multiple autoimmune conditions, the first of which are lupus, atopic dermatitis and psoriasis, and I'll talk more about those later on the call.

Let me first start with bempeg, our IL-2 pathway program in T cell stimulator. Earlier this year, we announced a revised collaboration agreement with our partner, BMS. Under the new joint development plan, we expanded the BMS-Nektar active registrational programs for the doublet of bempeg and nivo from the 3 studies that were underway to now include 7 studies in first-line and adjuvant settings, across 4 tumor types with more than 3,000 patients. The new registrational program builds upon the opportunity in melanoma, bladder cancer and renal cell carcinoma, and also adds plans for a Phase II study in first-line non-small cell lung cancer.

In addition to the 3 ongoing Registrational Trials in first-line metastatic melanoma, first-line cis-ineligible metastatic bladder cancer and first-line metastatic RCC, we've already launched a new Phase III study in muscle-invasive bladder cancer, and we are initiating a Phase III study in adjuvant melanoma. I will let Wei cover the design of these new Phase III studies in a moment.

The economics of the revised agreement reflect BMS's continued commitment to the collaboration. At a high level, if you look at BMS's share of clinical costs for the new joint development plan associated with the 7 studies, it is approximately $1.2 billion. There were also some enhancements to the economics for Nektar, which provide additional and accelerated near-term milestone payments. This includes a $25 million accelerated milestone payment that we received in Q1 of this year with the initiation of the MIBC study. It also includes a new $25 million milestone for Nektar at the start of the adjuvant melanoma study, which we expect will occur in Q3 of this year. In addition, the new agreement includes $75 million accelerated milestone payment at the start of the first Phase III registrational non-small cell lung cancer study with nivo. The rest of the economics are unchanged. BMS funds 2/3 of the development cost, Nektar contributes 1/3. Nektar books global revenues. The profit split is 65% Nektar, 35% to BMS. We're also entitled to $650 million in total milestone payments upon the first approvals of bempeg in U.S., Europe and Japan, and then $260 million per each of the next 3 approved indications for bempeg.

As many of you know, BMS is currently enrolling patients in our Registrational Trial in first-line metastatic melanoma, and all the investigator sites are now up and running. Last year, we obtained an FDA breakthrough therapy designation for bempeg plus nivo in patients with metastatic melanoma, based on the positive data, including complete response rate from our PIVOT-02 study. The Phase III study enrolling in this setting has 3 endpoints: ORR, PFS and OS. The current projected earliest time line for reaching the follow-up time period needed on the number of patients required for the first interim ORR endpoint is the end of Q4 2020 this year.

The PFS endpoint is projected to occur roughly 6 to 7 months later. But as a reminder, this is event-driven, and the timing could change. For both OOR and PFS, the results will be analyzed by blinded independent radiology review. So also keep in mind that this process will affect timing for the completion of any data analysis. So the first data readout will most likely be Q1 of '21. As we head closer, we should be able to refine this time line. As a reminder, ORR is designed as an accelerated approval endpoint. We spent only a small amount of alpha on this, and PFS is the full approval endpoint.

With the breakthrough designation, the potential for the doublet in melanoma is quite promising. And as part of our amended agreement with BMS, our 2 companies are excited to expand our development efforts into the adjuvant melanoma setting. This essentially doubles the number of patients that could potentially benefit from this doublet in melanoma and represents a significant opportunity for bempeg. Given BMS has the leadership position with nivolumab across all lines of therapy in melanoma, we're pleased that bempeg with nivolumab has the potential to further advance the standard of care in both early and advanced stage melanoma.

In bladder cancer, we are enrolling a 200-patient study in first-line cis-ineligible bladder cancer, which is intended to support a potential accelerated approval pathway in this setting, specifically in patients with PD-L1 low expression as defined by a CPS score under 10. We expect the first potential data on the ORR endpoint from this trial in Q2 or Q3 of '21. And to build on this opportunity in bladder cancer, we've also initiated a confirmatory Phase III study in patients with cis-ineligible muscle-invasive bladder cancer. This gives us the ability to capture the opportunity in both early and late-stage bladder cancer, expanding the potential for bempeg and nivo to help even more patients.

In metastatic first-line renal cell carcinoma, BMS and Nektar have chosen a comprehensive approach that positions the doublet with a TKI sparing and a TKI inclusive regimen. Our Phase III Registrational Study evaluating bempeg and nivo versus a TKI in first-line RCC is now enrolling nicely, and we are on track to potentially have the first interim OS readout in the first quarter of 2022.

The TKI inclusive regimen development work will start mid-year under the new BMS agreement and is designed to support a registrational path forward in a first-line metastatic RCC study with this triplet.

We will conduct a Phase I/II dose escalation and expansion study to evaluate bempeg plus nivo in combination with axi in first-line RCC to establish the dose and administration schedule for a future Registrational Trial.

Finally, BMS and Nektar agreed on a development path for the doublet in first-line non-small cell lung cancer that we believe positions bempeg nicely for a flexible registrational path forward in non-small cell lung cancer. BMS will run a dose optimization and expansion study to identify the appropriate dose regimen, and BMS is paying 100% of the cost of that program. And we will continue our work evaluating pembro with bempeg in non-small cell lung cancer in our PROPEL trial, which is currently enrolling patients. This gives us the flexibility in the future to evaluate moving forward with either nivo or pembro in non-small cell lung cancer.

We're pleased to have the renewed agreement in place and look forward to this phase of our collaboration. This structure also removes certain exclusivity restrictions from the old agreement for a list of indications for bempeg and so provides us enhanced flexibility to pursue other combinations for bempeg.

Along those lines, we're exploring the potential of bempeg with other checkpoint inhibitors and other mechanisms and expanding this work is a key role for us this year.

In collaboration with Pfizer, we have an ongoing Phase Ib/II study in head and neck cancer and castration-resistant prostate cancer. The study will evaluate bempeg and nivolumab in head and neck cancer and also evaluate 2 triplet combinations, bempeg plus avelumab plus talazoparib; and bempeg and avelumab and enzalutamide in prostate cancer.

We're very excited to work with Pfizer on this because of the opportunity in these 2 solid tumor settings for bempeg, particularly in patients with PD-L1 negative tumors. We also started a study in head and neck cancer in partnership with Vaccibody. The study combines bempeg with their personalized vaccine approach and could pave the way for a novel treatment regimen with bempeg in this tumor setting.

In addition, we have plans to start a study with BioXcel, combining their molecule, bempeg and Pfizer's avelumab in pancreatic cancer. As you can see, the bempeg program is emerging as 1 of the largest registrational and development programs in immuno-oncology, and we're excited about the potential of this novel agent to combine with checkpoints and other mechanisms.

Turning to our next immuno-oncology candidate, NKTR-262, our TLR7/8 agonist, our Phase I/II REVEAL study is advancing, and we recently achieved our recommended Phase II dose of NKTR-262 with bempeg. You'll recall that because this was a novel-novel combination, we had to evaluate staged dosing of NKTR-262 with bempeg in dose escalation. We've observed high levels of TLR activation in the tumor microenvironment and the dose escalation allows us to understand PK/PD and then characterize safety for NKTR-262.

Our current plan is to take the recommended Phase II dose of NKTR-262 into a focused expansion in at least 1 tumor type, starting with 24 relapsed and refractory melanoma patients. Based upon the biology of the innate and adaptive immune system interaction, we will now evaluate simultaneous dosing of the TLR and bempeg to explore the combination's potential in the I-O relapsed/refractory melanoma setting.

The scientific community is beginning to recognize the importance of natural killer cell biology in the treatment of cancer. And as many of you know, this area of research is generating much excitement.

So let me now turn to our newest clinical candidate, our IL-15 agonist program known as NKTR-255. NKTR-255 is designed to capture the full biology of the IL-15 pathway to cause both proliferation of NK cells and the expansion of CD8 memory cells, which provides us with a wide range of potential development pathways for NTKR-255.

Given the product profile, we're advancing towards forward on multiple fronts with this program and JZ will provide more details on the data emerging from this program, but let me provide a high-level overview of the progress on this promising mechanism. First, we're enrolling patients into our first-in-human clinical trial of NKTR-255, which began last year. The study is evaluating NKTR-255, first as a monotherapy, and then in combination with dara or rituximab in multiple myeloma and non-Hodgkin's lymphoma, respectively. In addition, we have 2 research collaborations ongoing with partners who are entirely funding the research. First, Janssen is conducting preclinical studies of NKTR-255 in combination with a number of their internal oncology mechanisms. And separately, in virology, Gilead is exploring the potential of NKTR-255 in nonhuman primate studies, in combination with a number of antivirals in their portfolio. So NKTR-255 has the potential to have many applications in oncology as well as, potentially, virology, and we look forward to its progress.

Moving on to NKTR-358, our Treg stimulatory program, which is partnered with Lilly. We reported significant progress with this program in 2019. Last year, first-in-human data in healthy volunteers were reported at EULAR, and these data demonstrated the candidate's dose-dependent and selected proliferation of Treg cells. We recently completed the Phase Ib multiple ascending dose study in lupus patients, and we have submitted these data to be presented at this year's EULAR meeting.

Our partner, Lilly, also recently initiated Phase Ib studies in 2 new autoimmune indications of psoriasis and atopic dermatitis, and these studies are ongoing and enrolling patients. Our partner, Lilly, also has plans to start a Phase II dose-ranging study in lupus in the middle of this year, and they plan to add another Phase II autoimmune indication to the development program this year.

So we're very pleased with their commitment and the broad nature of this development program, which reflects the potential of this novel mechanism to treat autoimmune diseases. And with that, I'd like to turn the call over to Wei to review the Phase III study design for bempeg. Wei?

--------------------------------------------------------------------------------

Wei Lin, Nektar Therapeutics - SVP & Head of Development [4]

--------------------------------------------------------------------------------

Thank you, Howard. I'd like to discuss briefly the comprehensive plan we've developed with our partner, BMS, for the doublet of bempeg plus nivolumab in the melanoma setting, an area where the IL-2 pathway has already been validated. As Howard stated, we have generated breakthrough designation-worthy data in first-line metastatic melanoma from our PIVOT-02 study of bempeg plus nivo. At a median follow-up of approximately 18 months, 34% of patients had a complete response as determined by blinded independent central review; 42% had a 100% reduction in target lesions; and 47%, almost half, had a greater than 75% reduction in target lesions.

The significance of deep responses in metastatic melanoma and its association with survival have recently been demonstrated by the FDA in a metanalysis they presented at ASCO 2019. Based on this analysis, patients who achieved a 75% or greater tumor shrinkage in their RECIST targ lesions, including patients that achieved a complete response, had very high likelihood of having the greatest improvement in progression-free survival and overall survival, especially if they were treated with immunotherapy. So objective response is very highly correlated with survival in melanoma with I-O agents.

With that context, our data from the PIVOT-02 study showing that nearly 1/2 of the melanoma patients had a 75% or greater response reinforces our confidence in the doublet in melanoma. And indeed, as we presented in November at SITC 2019, with approximately 18 months of follow-up, median PFS had not been reached. We plan to share updated data from this cohort at a future meeting in the second half of this year.

Our confidence in the potential clinical benefit that bempeg plus nivo may offer in melanoma has led us and BMS to initiate a study in the adjuvant setting. In this study, we evaluate the extended treatment of post-surgical patients with bempeg plus nivo with an endpoint of event-free survival.

The treatment duration will be 12 months. We estimate that the study will enroll between 900 and 1,000 patients and will compare the doublet of bempeg plus nivo to a single-agent nivolumab. We are finalizing the protocol with BMS and expect to start this trial in the second half of this year. Due to the long duration of adjuvant melanoma studies, we expect a potential first readout in 2024.

With the ongoing Phase III metastatic melanoma study and the new adjuvant study, BMS and Nektar now have a comprehensive approach to expanding the transformative potential of the bempeg/nivo doublet to more patients with melanoma. In addition, as Howard stated, in January, BMS started the new Phase III bladder cancer study, which is enrolling patients with muscle-invasive disease in the peri-adjuvant setting.

Our ongoing metastatic study in urothelial carcinoma is in the cisplatin-ineligible patients. And this new Phase III study extends our doublet into earlier disease for essentially the same patient population. In addition, the trial will also serve as the confirmatory study for a potential accelerated approval filing planned with our ongoing metastatic trial.

In the muscle-invasive study, we will stratify patients by stage and PD-L1 status. During the new adjuvant pre-surgical phase, 540 patients will be randomized into 3 arms to receive treatment with either bempeg plus nivo or nivo or no treatment at all, which is the current standard of care. Then after cystectomy, they will continue on the same pre-surgical treatment regimen for a 12-month period.

The primary endpoint will be pathologic complete response and event-free survival.

Again, this is a longer study and our first potential readout is expected to be in 2024. With that, I'll hand the call to JZ to discuss more on our NTKR-255 program.

--------------------------------------------------------------------------------

Jonathan Zalevsky, Nektar Therapeutics - Chief Research & Development Officer [5]

--------------------------------------------------------------------------------

Thanks, Wei. I'd like to spend a little more time discussing the IL-15 program, NKTR-255, as it is the next large cytokine program in our pipeline that is generating significant interest. NKTR-255 was designed to capture the full biology of the IL-15 pathway. Specifically meaning that NKTR-255 is designed to capture all the receptor ligand interactions available through targeting the IL-15 agonist pathway. As a consequence, NKTR-255 functions as a significant expander of natural killer cells and an agent that promotes the survival and expansion of memory CD8 T cells. The clinical and research community is increasingly recognizing the importance of NK cells and memory cells in the I-O cascade.

Now as I just stated, a key differentiating factor for NKTR-255 is that we have engineered it to bind to all forms of the IL-15 receptor versus other mutein proteins in development that only bind to beta gamma receptors. We believe that this will translate to enhanced efficacy. For example, we know that in order to support NK cell-mediated cellular killing, you need to induce intracellular granzyme B and data presented at SITC 2019 showed that we get maximal granzyme B production versus other muteins and even more than native IL-15.

Additional preclinical data we generated to date highlights the various combination opportunities for this candidate. First, we see an opportunity to combine with antibodies such as daratumumab and rituximab that work through an antibody-dependent cellular cytotoxicity or ADCC mechanism of action. In the ADCC reaction, antibodies bind to the target cell surface via the antigen recognition portion of the antibody. This coating of a cell with antigen recognizing antibodies is an immune process called opsonization. These opsonized cells are then recognized by NK cells via the Fc gamma receptors on the NK cells binding to the Fc region of antibodies on opsonized cells. The clustering of Fc gamma receptors promotes degranulation of the NK cells, leading to killing of the opsonized cells. In this way, the targeted antibody is able to selectively and specifically kill opsonized cells via the action of NK effector cells. However, one of the limitations of the ADCC reaction is that NK cells, the effector cells that actually promote the killing of opsonized cells, are consumed and themselves depleted in the ADCC reaction, consequently, limiting efficacy of the targeted antibody. If we are able to enhance the proliferation and function of NK cells by NKTR-255 and combine that with ADCC antibodies, we can see a very profound effect.

In nonclinical studies, NKTR-255 exhibited antitumor activity and substantially enhanced in vivo proliferation and activation of NK cells to provide sustained cytotoxic function.

In the preclinical lymphoma model, where single agent daratumumab was ineffective, NKTR-255 treatment in combination of daratumumab increased NK cell numbers and activity in bone marrow tissue and enhanced ADCC mediated tumor cell clearance in the bone marrow compartment. Now this is a very important result because it confirmed that NKTR-255 was able to mobilize functional NK cells in the bone marrow compartment, indicating that with NKTR-255, we can generate not only systemic, but also tissue-dependent effects.

More recently at ASH, we showed that NKTR-255 enhanced the number and function of both NK and CD8 effector memory T cell populations in the peripheral blood from healthy donors and from patients with multiple myeloma. NKTR-255 was also able to revert the inhibitory status of NK cells for multiple myeloma patients and showed synergy with daratumumab and elotuzumab to significantly increase the status of NK susceptibility of the multiple myeloma cells in a dose-dependent manner.

Collectively, these data provide a strong rationale for our first clinical study, which is now underway. The study is evaluating the safety and dose schedule of NKTR-255 as a monotherapy, and then will expand into combination with antibodies that work through an ADCC mechanism, including daratumumab and rituximab. We plan to enroll patients with relapsed or refractory multiple myeloma and non-Hodgkin's lymphoma in this study. The study will also evaluate pharmacokinetic and pharmacodynamic effects as well as antitumor activity. We have also introduced a robust biomarker program into this trial to provide a deep assessment of the NKTR-255 mechanism of action. Besides NK cells, we will also evaluate total and subpopulations of CD4 and CD8 memory T cells to study the effect of NKTR-255 on their expansion, activation and survival.

This biomarker-rich, early clinical development approach allows us to follow the science in the development and planning for NKTR-255. Our goal is to achieve initial results from the first monotherapy phase of this Phase I trial this year. In addition, our partners, Janssen and Gilead, may present data from their respective preclinical efforts with NKTR-255 as well. Now we also see potential for NKTR-255 in combination with CAR-T and other cell therapies. CAR-T is very effective, but only for a relatively short period of time. By adding IL-15 and promoting proliferation of memory T cells, we may be able to get a much more durable duration of response associated with CAR-T therapy. Our collaboration with Fred Hutchinson has yielded some impressive early data also presented at ASH. Specifically, researchers demonstrated NKTR-255 prevented tumor growth and increased survival of CAR-T cells when added to a CD19-targeted CAR-T cell regimen in models of B-cell lymphoma. With that update, let me turn the call over to Gil for a review of the financials.

--------------------------------------------------------------------------------

Gilbert M. Labrucherie, Nektar Therapeutics - Senior VP, CFO & COO [6]

--------------------------------------------------------------------------------

Thank you, JZ, and good afternoon, everyone. This afternoon, we announced our full year financial results for 2019 in our earnings press release. On this call, I will provide our annual financial guidance for 2020. Starting with our cash position, we exited 2019 with $1.6 billion of cash and investments. With our exceptionally strong cash position, we have decided to repay the $250 million of outstanding senior secured notes on our balance sheet. This will strengthen our balance sheet and improve our annual cash flow as it will result in approximately $20 million of annual interest savings on a go-forward basis. With respect to cash usage for R&D and operations, we expect to use approximately $350 million in net cash in 2020. This compares to net cash usage of $315 million in 2019. This increase in investment in 2020 is primarily a result of our plans to complete enrollment in the first-line Registrational Studies in melanoma, bladder, renal cell carcinoma as well as begin the 2 new Phase III studies we are initiating this year for the expanded bempeg development program under our BMS collaboration.

After taking account of our plan to repay the $250 million of debt in Q2, we expect to end 2020 with approximately $1 billion in cash and investments.

Now turning to revenue. Our GAAP revenue is expected to be between $140 million and $145 million this year. GAAP revenue includes $50 million of new and accelerated milestone payments from BMS under our expanded agreement. The first $25 million of these milestones will be recognized in Q1 for the start of the MIBC study, which occurred in January of this year. And the second $25 million milestone will be in connection with the start of the adjuvant melanoma study, which is currently planned for Q3. Excluding these milestones, we expect the remaining $90 million to $95 million of GAAP revenue to be fairly ratable over the 4 quarters of 2020, comprised of the following: $40 million to $42 million in cash royalties; $34 million to $36 million of noncash royalty revenue; $11 million to $12 million of product sales; and an additional $5 million in other licensed collaboration revenue outside of BMS.

We anticipate 2020 GAAP R&D expense will range between $475 million and $500 million, which includes approximately $70 million of noncash depreciation and stock compensation expense. We expect R&D expense to be fairly ratable over the 4 quarters of this year.

In addition to the R&D investment in the new trials in the expanded BMS collaboration, I would like to highlight a few other key areas of focus for us in 2020.

In order to meet our planned time line for BLA filing and potential commercial launch of bempeg in 2021, we plan to complete validation of our large-scale commercial manufacturing process and begin manufacture of commercial supplies this year. As a result, bempeg manufacturing costs will continue to be a significant component of our R&D expense in 2020.

Under our BMS collaboration, BMS shares 35% of bempeg manufacturing costs. In addition, we will continue to invest in development of bempeg outside of the BMS collaboration, including our PROPEL study with pembrolizumab in non-small cell lung cancer. And in combination with other modalities under our collaborations with Pfizer, BioXcel and Vaccibody. Our R&D expense also includes the initiation of 2 Phase II studies for NKTR-358, and the ongoing Phase Ib studies in atopic dermatitis and psoriasis. As Howard stated, the first Phase II study in lupus is planned to begin midyear, and the second Phase II study in a new autoimmune disease state will start in the second half of 2020. As a reminder, in our collaboration with Lilly, we are responsible for 25% of these costs.

In addition, we will continue to invest in our Phase I/II work for NKTR-255 and NKTR-262. G&A expense for 2020 is projected to be between $105 million and $115 million, which includes approximately $45 million of noncash depreciation and stock compensation expense. For 2020, GAAP interest income will be approximately $30 million to $33 million. With repayment of our senior notes, we expect 2020 full year interest expense of $7 million to $8 million as compared to $21.3 million in 2019. We also expect to recognize between $26 million and $28 million in noncash interest expense related to the legacy CIMZIA and MIRCERA royalty monetization. In Q1 of this year, we plan to record an impairment charge on our income statement of between $45 million and $50 million related to the discontinuation of the NKTR-181 program. This impairment charge is composed of 2 parts: noncash charges of approximately $20 million and cash payments of $25 million to $30 million, primarily related to certain non-cancelable contract manufacturing commitments.

As I stated earlier, we plan to end 2020 with approximately $1 billion in cash and investments after repayment of our $250 million in senior secured notes.

And with that, we will open the call for questions. Operator?

================================================================================

Questions and Answers

--------------------------------------------------------------------------------

Operator [1]

--------------------------------------------------------------------------------

(Operator Instructions) And our first question comes from Chris Shibutani from Cowen.

--------------------------------------------------------------------------------

Chris Shibutani, Cowen and Company, LLC, Research Division - MD & Senior Research Analyst [2]

--------------------------------------------------------------------------------

With the bempeg programs in lung, can you give us a sense for how enrollment is progressing, both with the program with OPDIVO as well as with pembro? I think historically, there have been some bumps in the road. Can you talk about what initiatives you have put in place that may be helping to engender confidence in your time lines?

--------------------------------------------------------------------------------

Wei Lin, Nektar Therapeutics - SVP & Head of Development [3]

--------------------------------------------------------------------------------

This is Wei Lin. I'll take that question. So regarding the -- our bempeg combination in lung, as been stated in the call, our strategy is really 2-prong: in combination with pembrolizumab; as well as combination with nivolumab. First of all, the combination with pembrolizumab, that's being operationalized by Nektar. And we expect -- so that study has started enrollment. And we expect by the end of the year to have 10 to 20 patients' worth of data that has a sufficient follow-up, at least 2 scans, to allow for data assessment of activity. The combination with nivolumab, that's being operationalized fully by BMS. And that study has not opened yet, and we'll provide more details as the year goes along.

--------------------------------------------------------------------------------

Chris Shibutani, Cowen and Company, LLC, Research Division - MD & Senior Research Analyst [4]

--------------------------------------------------------------------------------

Great. And then with 255, which seems to be an asset that JZ highlighted here, can you give us a sense, maybe frame what kind of efficacy results we may see in the monotherapy setting for those 2 indications that we are likely to see data, the myeloma, et cetera?

--------------------------------------------------------------------------------

Jonathan Zalevsky, Nektar Therapeutics - Chief Research & Development Officer [5]

Read more here:
Edited Transcript of NKTR earnings conference call or presentation 27-Feb-20 10:00pm GMT - Yahoo Finance

The Pancreatic Cancer Collective awards additional funding of $16 million for new therapies – The Medical News

The Pancreatic Cancer Collective, the strategic partnership of Lustgarten Foundation and Stand Up To Cancer (SU2C), has awarded additional funding of up to $16 million to four teams of top researchers as part of its "New Therapies Challenge Grants," the American Association for Cancer Research (AACR), Scientific Partner of SU2C, announced today.

The additional support builds on a first round of funding announced in November 2018. These four teams originally received up to $1 million each to pursue preclinical work over 13 months, including several projects seeking to repurpose drugs approved for other uses for their potential to treat pancreatic cancer. These teams demonstrated the most promising preliminary results to allow them to take potential therapies into clinical trials. Pancreatic cancer is one of the deadliest forms of cancer, with a five-year survival rate of about 9 percent, according to the National Cancer Institute.

"These 'Challenge Grants' seeking new treatments for pancreatic cancer are working exactly as intended," said Phillip A. Sharp, PhD, the Nobel laureate and MIT scientist who serves as chair of the SU2C Scientific Advisory Committee. "These are important new investigations that have the potential to save lives with new approaches to therapy."

Each team will receive up to $4 million over a three-year term for the studies focused on clinical trials.

We are impressed by the results of the first round. Under this phased 'Challenge Grant' approach, teams are accelerating pre-clinical work and we are very eager to take the next step to bring new applications for pancreatic cancer treatment to clinical studies."

David A. Tuveson, MD, PhD, chief scientist of the Lustgarten Foundation and director of the cancer center at Cold Spring Harbor Laboratory in New York

"It is gratifying to see the initial success of the New Therapies Challenge project, which we created to accelerate the research process and bring improved treatment options to patients," said Kerri Kaplan, president and CEO of the Lustgarten Foundation. "Through the Pancreatic Cancer Collective, these two leading cancer organizations have demonstrated the strength of collaboration. We are excited for the potential for breakthroughs in effective pancreatic cancer treatments and, eventually, a cure for this deadly disease."

The AACR will support the administration of these projects receiving funding for the second round, including:

Targeting SHP2 in Pancreatic Cancer: Team leader: Rene Bernards, PhD, Netherlands Cancer Institute; co-leaders: Hana Algl, MD, PhD, Technical University of Munich, and Emile E. Voest, MD, PhD, Netherlands Cancer Institute. The team focuses on pancreatic tumors that have a mutation in the KRAS gene and has conducted preclinical testing of drug combinations that inhibit certain proteins in the malignant cells. In the second stage, the team will move into a phase I/Ib clinical trial to test the combination of SHP2 inhibitors (RMC4630) and ERK inhibitors (LY3214996). The results are expected to lay the basis for a phase II clinical trial.

Exploiting DNA Repair Gene Mutations in Pancreatic Cancer: Team leader: Alan D'Andrea, MD, Dana-Farber Cancer Institute; co-leader: James Cleary, MD, PhD, Dana-Farber Cancer Institute. The team has been seeking to evaluate DNA repair inhibitors and improve the use of PARP inhibitors, which interfere with the ability of cancerous cells to increase in number. The team's preclinical data suggests that combining gemcitabine with inhibitors that target regulatory proteins involved in DNA repair could be an effective therapy in platinum-resistant pancreatic cancer. Based on these laboratory findings, the team is developing three pancreatic cancer clinical trials testing gemcitabine-based combinations: gemcitabine/ATR inhibitor BAY1895344; gemcitabine/CHK1 inhibitor LY2880070; and gemcitabine/WEE1 inhibitor AZD1775. The most promising combinations will be identified for potential validation in larger trials.

Immunotherapy Targeting Mutant KRAS (mKRAS): Leader: Robert H. Vonderheide, MD, DPhil, Abramson Cancer Center at the University of Pennsylvania; co-leaders: Elizabeth M. Jaffee, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and Beatriz Carreno, PhD, Abramson Cancer Center at the University of Pennsylvania. The team is developing an immunological approach to target mutations in the molecule KRAS, an underlying cause of most cases of pancreatic cancer. In the first round of funding, the team used innovative strategies in bioinformatics, biochemistry, and cell biology to identify specific mKRAS protein sequences that can be recognized by T cells. They then isolated a series of molecular receptors that enable T cells to home in on cancer cells expressing mKRAS. Based on these findings, the team is conducting two different clinical trials with novel vaccines aimed at triggering mKRAS immune responses in patients with resected pancreatic cancer. In round two of funding, the team plans to use the most promising T-cell receptor identified and conduct a clinical trial of engineered T-cell therapy for patients with metastatic pancreatic cancer.

Molecularly Targeted Radionuclide Therapy via the Integrin v?6; Team Leader: Julie Sutcliffe, PhD, University of California Davis; co-leader: Richard Bold, MD, University of California Davis. The team has been working to develop a peptide receptor radionuclide therapy (PRRT) that involves homing in on a protein called integrin v6, a cell surface receptor that can be found in pancreatic cancers. The team has synthesized in the laboratory a pair of related peptide constructs that are tagged with two different radiolabels. One radiolabel facilitates the imaging of pancreatic cancer lesions in patients that can more likely benefit from the PRRT. The other radiolabel can facilitate the killing of the pancreatic cancer cells. The team has obtained promising results in the laboratory testing of the peptide constructs. In the second round of funding, the team will conduct a phase 1, first-in-human study to evaluate the feasibility, safety and efficacy of the two peptide constructs. The study will determine if one construct can detect lesions in patients with locally advanced or metastatic pancreatic cancer; establish the safety and tolerability of the pair; evaluate the maximum tolerated dose of the second construct; and, using pre-clinical models, establish an optimal dosing regimen.

The Lustgarten Foundation and Stand Up To Cancer have collaborated closely since 2012, jointly funding more than 400 investigators from nearly 70 leading research centers in the United States and the United Kingdom. These efforts include 18 multi-institutional teams, including Convergence Teams bringing together computational experts with clinical oncologists, and cancer interception -- research supporting the earliest diagnosis of pancreatic cancer, even before the cancer may have fully formed. All told, these collaborative teams have planned, started, or completed nearly 30 clinical trials. The Pancreatic Cancer Collective is building on this momentum to push the boundaries of what can be accomplished even further.

Read more:
The Pancreatic Cancer Collective awards additional funding of $16 million for new therapies - The Medical News

Biochemical and structural cues of 3D-printed matrix synergistically direct MSC differentiation for functional sweat gland regeneration – Science…

Abstract

Mesenchymal stem cells (MSCs) encapsulation by three-dimensionally (3D) printed matrices were believed to provide a biomimetic microenvironment to drive differentiation into tissue-specific progeny, which made them a great therapeutic potential for regenerative medicine. Despite this potential, the underlying mechanisms of controlling cell fate in 3D microenvironments remained relatively unexplored. Here, we bioprinted a sweat gland (SG)like matrix to direct the conversion of MSC into functional SGs and facilitated SGs recovery in mice. By extracellular matrix differential protein expression analysis, we identified that CTHRC1 was a critical biochemical regulator for SG specification. Our findings showed that Hmox1 could respond to the 3D structure activation and also be involved in MSC differentiation. Using inhibition and activation assay, CTHRC1 and Hmox1 synergistically boosted SG gene expression profile. Together, these findings indicated that biochemical and structural cues served as two critical impacts of 3D-printed matrix on MSC fate decision into the glandular lineage and functional SG recovery.

Mesenchymal stem cells (MSCs) hold great promise for therapeutic tissue engineering and regenerative medicine, largely because of their capacity for self-renewal and multipotent properties (1). However, their uncertain fate has a major impact on their envisioned therapeutic use. Cell fate regulation requires specific transcription programs in response to environmental cues (2, 3). Once stem cells are removed from their microenvironment, their response to environmental cues, phenotype, and functionality could often be altered (4, 5). In contrast to growing information concerning transcriptional regulation, guidance from the extracellular matrix (ECM) governing MSC identity and fate determination is not well understood. It remains an active area of investigation and may provide previously unidentified avenues for MSC-based therapy.

Over the past decade, engineering three-dimensional (3D) ECM to direct MSC differentiation has demonstrated great potential of MSCs in regenerative medicine (6). 3D ECM has been found to be useful in providing both biochemical and biophysical cues and to stabilize newly formed tissues (7). Culturing cells in 3D ECM radically alters the interfacial interactions with the ECM as compared with 2D ECM, where cells are flattened and may lose their differentiated phenotype (8). However, one limitation of 3D materials as compared to 2D approaches was the lack of spatial control over chemistry with 3D materials. One possible solution to this limitation is 3D bioprinting, which could be used to design the custom scaffolds and tissues (9).

In contrast to traditional engineering techniques, 3D cell printing technology is especially advantageous because it can integrate multiple biophysical and biochemical cues spatially for cellular regulation and ensure complex structures with precise control and high reproducibility. In particular, for our final goal of clinical practice, extrusion-based bioprinting may be more appropriate for translational application. In addition, as a widely used bioink for extrusion bioprinting, alginate-based hydrogel could maintain stemness of MSC due to the bioinert property and improve biological activity and printability by combining gelatin (10).

Sweat glands (SGs) play a vital role in thermal regulation, and absent or malfunctioning SGs in a hot environment can lead to hyperthermia, stroke, and even death in mammals (11, 12). Each SG is a single tube consisting of a functionally distinctive duct and secretory portions. It has low regenerative potential in response to deep dermal injury, which poses a challenge for restitution of lost cells after wound (13). A major obstacle in SG regeneration, similar to the regeneration of most other glandular tissues, is the paucity of viable cells capable of regenerating multiple tissue phenotypes (12). Several reports have described SG regeneration in vitro; however, dynamic morphogenesis was not identified nor was the overall function of the formed tissues explored (1416). Recent advances in bioprinting and tissue engineering led to the complexities in the matrix design and fabrication with appropriate biochemical cues and biophysical guidance for SG regeneration (1719).

Here, we adopted 3D bioprinting technique to mimic the regenerative microenvironment that directed the specific SG differentiation of MSCs and ultimately guided the formation and function of glandular tissue. We used alginate/gelatin hydrogel as bioinks in this present study due to its good cytocompatibility, printability, and structural maintenance in long-time culture. Although the profound effects of ECM on cell differentiation was well recognized, the importance of biochemical and structural cues of 3D-printed matrix that determined the cell fate of MSCs remained unknown; thus, the present study demonstrated the role of 3D-printed matrix cues on cellular behavior and tissue morphogenesis and might help in developing strategies for MSC-based tissue regeneration or directing stem cell lineage specification by 3D bioprinting.

The procedure for printing the 3D MSC-loaded construct incorporating a specific SG ECM (mouse plantar region dermis, PD) was shown schematically in Fig. 1A. A 3D cellular construct with cross section 30 mm 30 mm and height of 3 mm was fabricated by using the optimized process parameter (20). The 3D construct demonstrated a macroporous grid structure with hydrogel fibers evenly distributed according to the computer design. Both the width of the fibers and the gap between the fibers were homogeneous, and MSCs were embedded uniformly in the hydrogel matrix fibers to result in a specific 3D microenvironment. (Fig. 1B).

(A) Schematic description of the approach. (B) Full view of the cellular construct and representative microscopic and fluorescent images and the quantitative parameters of 3D-printed construct (scale bars, 200 m). Photo credit: Bin Yao, Wound Healing and Cell Biology Laboratory, Institute of Basic Medical Sciences, General Hospital of PLA. (C) Representative microscopy images of cell aggregates and tissue morphology at 3, 7, and 14 days of culture (scale bars, 50 m) and scanning electron microscopy (sem) images of 3D structure (scale bars, 20 m). PD+/PD, 3D construct with and without PD. (D) DNA contents, collagen, and GAGs of native tissue and PD. (E) Proliferating cells were detected through Ki67 stain at 3, 7, and 14 days of culture. (F) Live/dead assay show cell viability at days 3, 7, and 14. *P < 0.05.

During the maintenance of constructs for stem cell expansion, MSCs proliferated to form aggregates of cells but self-assembled to an SG-like structure only with PD administration (Fig. 1C and fig. S1, A to C). We carried out DNA quantification assay to evaluate the cellular content in PD and found the cellular matrix with up to 90% reduction, only 3.4 0.7 ng of DNA per milligram tissue remaining in the ECM. We also estimated the proportions of collagen and glycosaminoglycans (GAGs) in ECM through hydroxyproline assay and dimethylmethylene blue assay, the collagen contents could increase to 112.6 11.3%, and GAGs were well retained to 81 9.6% (Fig. 1D). Encapsulated cells were viable, with negligible cell death apparent during extrusion and ink gelation by ionic cross-linking, persisting through extended culture in excess of 14 days. The fluorescence intensity of Ki67 of MSCs cultured in 2D condition decreased from days 3 (152.7 13.4) to 14 (29.4 12.9), while maintaining higher intensity of MSCs in 3D construct (such as 211.8 19.4 of PD+3D group and 209.1 22.1 of PD3D group at day 14). And the cell viability in 3D construct was found to be sufficiently high (>80%) when examined on days 3, 7, and 14. The phenomenon of cell aggregate formation and increased cell proliferation implied the excellent cell compatibility of the hydrogel-based construct and promotion of tissue development of 3D architectural guides, which did not depend on the presence or absence of PD (Fig. 1, E and F).

The capability of 3D-printed construct with PD directing MSC to SGs in vitro was investigated. The 3D construct was dissolved, and cells were isolated at days 3, 7, and 14 for transcriptional analysis. Expression of the SG markers K8 and K18 was higher from the 3D construct with (3D/PD+) than without PD (3D/PD); K8 and K18 expression in the 3D/PD construct was similar to with control that MSCs cultured in 2D condition, which implied the key role of PD in SG specification. As compared with the 2D culture condition, 3D administration (PD+) up-regulated SG markers, which indicated that the 3D structure synergistically boosted the MSC differentiation (Fig. 2A).

(A) Transcriptional expression of K8, K18, Fxyd2, Aqp5, and ATP1a1 in 3D-bioprinted cells with and without PD in days 3, 7, and 14 culture by quantitative real-time polymerase chain reaction (qRT-PCR). Data are means SEM. (B) Comparison of SG-specific markers K8 and K18 in 3D-bioprinted cells with and without PD (K8 and K18, red; DAPI, blue; scale bars, 50 m). (C and D) Comparison of SG secretion-related markers ATP1a1 (C) and Ca2+ (D) in 3D-bioprinted cells with and without PD [ATP1a1 and Ca2+, red; 4,6-diamidino-2-phenylindole (DAPI), blue; scale bars, 50 m].

In addition, we tested secretion-related genes to evaluate the function of induced SG cells (iSGCs). Although levels of the ion channel factors of Fxyd2 and ATP1a1 were increased notably in 2D culture with PD and ATP1a1 up-regulated in the 3D/PD construct, all the secretory genes of Fxyd2, ATP1a1, and water transporter Aqp5 showed the highest expression level in the 3D/PD+ construct (Fig. 2A). Considering the remarkable impact, further analysis focused on 3D constructs.

Immunofluorescence staining confirmed the progression of MSC differentiation. At day 7, cells in the 3D/PD+ construct began to express K8 and K18, which was increased at day 14, whereas cells in the 3D/PD construct did not express K8 and K18 all the time (Fig. 2B and fig. S2A). However, the expression of ATP1a1 (ATPase Na+/K+ transporting subunit alpha 1) and free Ca2+ concentration did not differ between cells in the 3D/PD+ and 3D/PD constructs (Fig. 2, C and D). By placing MSCs in such a 3D environment, secretion might be stimulated by rapid cell aggregation without the need for SG lineage differentiation. Cell aggregationimproved secretion might be due to the benefit of cell-cell contact (fig. S2B) (21, 22).

To map the cell fate changes during the differentiation between MSCs and SG cells, we monitored the mRNA levels of epithelial markers such as E-cadherin, occludin, Id2, and Mgat3 and mesenchymal markers N-cadherin, vimentin, Twist1, and Zeb2. The cells transitioned from a mesenchymal status to a typical epithelial-like status accompanied by mesenchymal-epithelial transition (MET), then epithelial-mesenchymal transition (EMT) occurred during the further differentiation of epithelial lineages to SG cells (fig. S3A). In addition, MET-related genes were dynamically regulated during the SG differentiation of MSCs. For example, the mesenchymal markers N-cadherin and vimentin were down-regulated from days 1 to 7, which suggested cells losing their mesenchymal phenotype, then were gradually up-regulated from days 7 to 10 in their response to the SG phenotype and decreased at day 14. The epithelial markers E-cadherin and occludin showed an opposite expression pattern: up-regulated from days 1 to 5, then down-regulated from days 7 to 10 and up-regulated again at day 14. The mesenchymal transcriptional factors ZEB2 and Twist1 and epithelial transcriptional factors Id2 and Mgat3 were also dynamically regulated.

We further analyzed the expression of these genes at the protein level by immunofluorescence staining (figs. S3B and S4). N-cadherin was down-regulated from days 3 to 7 and reestablished at day 14, whereas E-cadherin level was increased from days 3 to 7 and down-regulated at day 14. Together, these results indicated that a sequential and dynamic MET-EMT process underlie the differentiation of MSCs to an SG phenotype, perhaps driving differentiation more efficiently (23). However, the occurrence of the MET-EMT process did not depend on the presence of PD. Thus, a 3D structural factor might also participate in the MSC-specific differentiation (fig. S3C).

To investigate the underlying mechanism of biochemical cues in lineage-specific cell fate, we used quantitative proteomics analysis to screen the ECM factors differentially expressed between PD and dorsal region dermis (DD) because mice had eccrine SGs exclusively present in the pads of their paws, and the trunk skin lacks SGs. In total, quantitative proteomics analyses showed higher expression levels of 291 proteins in PD than DD. Overall, 66 were ECM factors: 23 were significantly up-regulated (>2-fold change in expression). We initially determined the level of proteins with the most significant difference after removing keratins and fibrin: collagen triple helix repeat containing 1 (CTHRC1) and thrombospondin 1 (TSP1) (fig. S5). Western blotting was performed to further confirm the expression level of CTHRC1 and TSP1, and we then confirmed that immunofluorescence staining at different developmental stages in mice revealed increased expression of CTHRC1 in PD with SG development but only slight expression in DD at postnatal day 28, while TSP1 was continuously expressed in DD and PD during development (Fig. 3, A to C). Therefore, TSP1 was required for the lineage-specific function during the differentiation in mice but was not dispensable for SG development.

(A and B) Differential expression of CTHRC1 and TSP1in PD and back dermis (DD) ECM of mice by proteomics analysis (A) and Western blotting (B). (C) CTHRC1 and TSP1 expression in back and plantar skin of mice at different developmental times. (Cthrc1/TSP1, red; DAPI, blue; scale bars, 50 m).

According to previous results of the changes of SG markers, 3D structure and PD were both critical to SG fate. Then, we focused on elucidating the mechanisms that underlie the significant differences observed in 2D and 3D conditions with or without PD treatment. To this end, we performed transcriptomics analysis of MSCs, MSCs treated with PD, MSCs cultured in 3D construct, and MSC cultured in 3D construct with PD after 3-day treatment. We noted that the expression profiles of MSCs treated with 3D, PD, or 3D/PD were distinct from the profiles of MSCs (Fig. 4A). Through Gene Ontology (GO) enrichment analysis of differentially expressed genes, it was shown that PD treatment in 2D condition induced up-regulation of ECM and inflammatory response term, and the top GO term for MSCs in 3D construct was ECM organization and extracellular structure organization. However, for the MSCs with 3D/PD treatment, we found very significant overrepresentation of GO term related to branching morphogenesis of an epithelial tube and morphogenesis of a branching structure, which suggested that 3D structure cues and biochemical cues synergistically initiate the branching of gland lineage (fig S6). Heat maps of differentially expressed ECM organization, cell division, gland morphogenesis, and branch morphogenesis-associated genes were shown in fig. S7. To find the specific genes response to 3D structure cues facilitating MSC reprogramming, we analyzed the differentially expressed genes of four groups of cells (Fig. 4B). The expression of Vwa1, Vsig1, and Hmox1 were only up-regulated with 3D structure stimulation, especially the expression of Hmox1 showed a most significant increase and even showed a higher expression addition with PD, which implied that Hmox1 might be the transcriptional driver of MSC differentiation response to 3D structure cues. Differential expression of several genes was confirmed by quantitative polymerase chain reaction (qPCR): Mmp9, Ptges, and Il10 were up-regulated in all the treated groups. Likewise, genes involving gland morphogenesis and branch morphogenesis such as Bmp2, Tgm2, and Sox9 showed higher expression in 3D/PD-treated group. Bmp2 was up-regulated only in 3D/PD-treated group, combined with the results of GO analysis, we assumed that Bmp2 initiated SG fate through inducing branch morphogenesis and gland differentiation (Fig. 4C).

(A) Gene expression file of four groups of cells (R2DC, MSCs; R2DT, MSC with PD treatment; R3DC, MSC cultured in 3D construct; and R3DT, MSC treated with 3D/PD). (B) Up-regulated genes after treatment (2DC, MSCs; 2DT, MSC with PD treatment; 3DC, MSC cultured in 3D construct; and 3DT, MSC treated with 3D/PD). (C) Differentially expressed genes were further validated by RT-PCR analysis. [For all RT-PCR analyses, gene expression was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) with 40 cycles, data are represented as the means SEM, and n = 3].

To validate the role of HMOX1 and CTHRC1 in the differentiation of MSCs to SG lineages, we analyzed the gene expression of Bmp2 by regulating the expression of Hmox1 and CTHRC1 based on the 3D/PD-treated MSCs. The effects of caffeic acid phenethyl ester (CAPE) and tin protoporphyrin IX dichloride (Snpp) on the expression of Hmox1 were evaluated by quantitative real-time (qRT)PCR. Hmox1 expression was significantly activated by CAPE and reduced by Snpp. Concentration of CTHRC1 was increased with recombinant CTHRC1 and decreased with CTHRC1 antibody. That is, it was negligible of the effects of activator and inhibitor of Hmox1 and CTHRC1 on cell proliferation (fig. S8, A and B). Hmox1 inhibition or CTHRC1 neutralization could significantly reduce the expression of Bmp2, while Hmox1 activation or increased CTHRC1 both activated Bmp2 expression. Furthermore, Bmp2 showed highest expression by up-regulation of Hmox1 and CTHRC1 simultaneously and sharply decreased with down-regulation of Hmox1 and CTHRC1 at the same time (Fig. 5A). Immunofluorescent staining revealed that the expression of bone morphogenetic protein 2 (BMP2) at the translational level with CTHRC1 and Hmox1 regulation showed a similar trend with transcriptional changes (Fig. 5B). Likewise, the expression of K8 and K18 at transcriptional and translational level changed similarly with CTHRC1 and Hmox1 regulation (fig. S9, A and B). These results suggested that CTHRC1 and Hmox1 played an essential role in SG fate separately, and they synergistically induced SG direction from MSCs (Fig. 5C).

(A and B) Transcriptional analysis (A) and translational analysis (PD, MSCs; PD+, MSCs with 3D/PD treatment; CAPE, MSCs treated with 3D/PD and Hmox1 activator; Snpp, MSCs treated with 3D/PD and Hmox1 inhibitor; Cthrc1, MSCs treated with 3D/PD and recombinant CTHRC1; anti, MSCs treated with 3D/PD and CTHRC1 antibody: +/+, MSCs treated with 3D/PD and Hmox1 activator and recombinant CTHRC1; and /, MSCs treated with 3D/PD and Hmox1 inhibitor and CTHRC1 antibody. Data are represented as the means SEM and n = 3) (B) of bmp2 with regulation of CTHRC1 and Hmox1. (C) The graphic illustration of 3D-bioprinted matrix directed MSC differentiation. CTHRC1 is the main biochemical cues during SG development, and structural cues up-regulated the expression of Hmox1 synergistically initiated branching morphogenesis of SG. *P < 0.05.

Next, we sought to assess the repair capacity of iSGCs for in vivo implications, the 3D-printed construct with green fluorescent protein (GFP)labeled MSCs was transplanted in burned paws of mice (Fig. 6A). We measured the SG repair effects by iodine/starch-based sweat test at day 14. Only mice with 3D/PD treatment showed black dots on foot pads (representing sweating), and the number increased within 10 min; however, no black dots were observed on untreated and single MSC-transplanted mouse foot pads even after 15 min (Fig. 6B). Likewise, hematoxylin and eosin staining analysis revealed SG regeneration in 3D/PD-treated mice (Fig. 6C). GFP-positive cells were characterized as secretory lumen expressing K8, K18, and K19. Of note, the GFP-positive cells were highly distributed in K14-positive myoepithelial cells of SGs but were absent in K14-positive repaired epidermal wounds (Fig. 6, D and E). Thus, differentiated MSCs enabled directed restitution of damaged SG tissues both at the morphological and functional level.

(A) Schematic illustration of approaches for engineering iSGCs and transplantation. (B) Sweat test of mice treated with different cells. Photo credit: Bin Yao, Wound Healing and Cell Biology Laboratory, Institute of Basic Medical Sciences, General Hospital of PLA. (C) Histology of plantar region without treatment and transplantation of MSCs and iSGCs (scale bars, 200 m). (D) Involvement of GFP-labeled iSGCs in directed regeneration of SG tissue in thermal-injured mouse model (K14, red; GFP, green; DAPI, blue; scale bar, 200 m). (E) SG-specific markers K14, K19, K8, and K18 detected in regenerated SG tissue (arrows). (K14, K19, K8, and K18, red; GFP, green; scale bars, 50 m).

A potential gap in MSC-based therapy still exists between current understandings of MSC performance in vivo in their microenvironment and their intractability outside of that microenvironment (24). To regulate MSCs differentiation into the right phenotype, an appropriate microenvironment should be created in a precisely controlled spatial and temporal manner (25). Recent advances in innovative technologies such as bioprinting have enabled the complexities in the matrix design and fabrication of regenerative microenvironments (26). Our findings demonstrated that directed differentiation of MSCs into SGs in a 3D-printed matrix both in vitro and in vivo was feasible. In contrast to conventional tissue-engineering strategies of SG regeneration, the present 3D-printing approach for SG regeneration with overall morphology and function offered a rapid and accurate approach that may represent a ready-to-use therapeutic tool.

Furthermore, bioprinting MSCs successfully repaired the damaged SG in vivo, suggesting that it can improve the regenerative potential of exogenous differentiated MSCs, thereby leading to translational applications. Notably, the GFP-labeled MSC-derived glandular cells were highly distributed in K14-positive myoepithelial cells of newly formed SGs but were absent in K14-positive repaired epidermal wounds. Compared with no black dots were observed on single MSC-transplanted mouse foot pads, the black dots (representing sweating function) can be observed throughout the entire examination period, and the number increased within 10 min on MSC-bioprinted mouse foot pads. Thus, differentiated MSCs by 3D bioprinting enabled exclusive restitution of damaged SG tissues morphologically and functionally.

Although several studies indicated that engineering 3D microenvironments enabled better control of stem cell fates and effective regeneration of functional tissues (2730), there were no studies concerning the establishment of 3D-bioprinted microenvironments that can preferentially induce MSCs differentiating into glandular cells with multiple tissue phenotypes and overall functional tissue. To find an optimal microenvironment for promoting MSC differentiation into specialized progeny, biochemical properties are considered as the first parameter to ensure SG specification. In this study, we used mouse PD as the main composition of a tissue-specific ECM. As expected, this 3D-printed PD+ microenvironment drove the MSC fate decision to enhance the SG phenotypic profile of the differentiated cells. By ECM differential protein expression analysis, we identified that CTHRC1 was a critical biochemical regulator of 3D-printed matrix for SG specification. TSP1 was required for the lineage-specific function during the differentiation in mice but was not dispensable for SG development. Thus, we identified CTHRC1 as a specific factor during SG development. To our knowledge, this is the first demonstration of CTHRC1 involvement in dictating MSC differentiation to SG, highlighting a potential therapeutic tool for SG injury.

The 3D-printed matrix also provided architectural guides for further SG morphogenesis. Our results clearly show that the 3D spatial dimensionality allows for better cell proliferation and aggregation and affect the characteristics of phenotypic marker expression. Notably, the importance of 3D structural cues on MSC differentiation was further proved by MET-EMT process during differentiation, where the influences did not depend on the presence of biochemical cues. To fully elucidate the underlying mechanisms, we first examined how 3D structure regulating stem cell fate choices. According to our data, Hmox1 is highly up-regulated in 3D construct, which were supposed to response to hypoxia, with a previously documented role in MSC differentiation (31, 32). It is suggested that 3D microenvironment induced rapid cell aggregation leading to hypoxia and then activated the expression of Hmox1.

Through regulation of the expression of Hmox1 and addition or of CTHRC1 in the matrix, we confirmed that each of them is critical for SG reprogramming, respectively. Thus, biochemical and structural cues of 3D-printed matrix synergistically creating a microenvironment could enhance the accuracy and efficiency of MSC differentiation, thereby leading to resulting SG formation. Although we further need a more extensive study examining the role of other multiple cues and their possible overlap function in regulating MSC differentiation, our findings suggest that CTHRC1 and Hmox1 provide important signals that cooperatively modulate MSC lineage specification toward sweat glandular lineage. The 3D structure combined with PD stimulated the GO functional item of branch morphogenesis and gland formation, which might be induce by up-regulation of Bmp2 based on the verification of qPCR results. Although our results could not rule out the involvement of other factors and their possible overlapping role in regulating MSC lineage specification toward SGs, our findings together with several literatures suggested that BMP2 plays a critical role in inducing branch morphogenesis and gland formation (3335).

In summary, our findings represented a novel strategy of directing MSC differentiation for functional SG regeneration by using 3D bioprinting and pave the way for a potential therapeutic tool for other complex glandular tissues as well as further investigation into directed differentiation in 3D conditions. Specifically, we showed that biochemical and structural cues of 3D-printed matrix synergistically direct MSC differentiation, and our results highlighted the importance of 3D-printed matrix cues as regulators of MSC fate decisions. This avenue opens up the intriguing possibility of shifting from genetic to microenvironmental manipulations of cell fate, which would be of particular interest for clinical applications of MSC-based therapies.

The main aim and design of the study was first to determine whether by using 3D-printed microenvironments, MSCs can be directed to differentiate and regenerate SGs both morphologically and functionally. Then, to investigate the underlying molecular mechanism of biochemical and structural cues of 3D-printed matrix involved in MSCs reprogramming. The primary aims of the study design were as follows: (i) cell aggregation and proliferation in a 3D-bioprinted construct; (ii) differentiation of MSCs at the cellular phenotype and functional levels in the 3D-bioprinted construct; (iii) the MET-EMT process during differentiation; (iv) differential protein expression of the SG niche in mice; (v) differential genes expression of MSCs in 3D-bioprinted construct; (vi) the key role of CTHRC1 and HMOX1 in MSCs reprogramming to SGCs; and (vii) functional properties of regenerated SG in vivo.

Gelatin (Sigma-Aldrich, USA) and sodium alginate (Sigma-Aldrich, USA) were dissolved in phosphate-buffered saline (PBS) at 15 and 1% (w/v), respectively. Both solutions were sterilized under 70C for 30 min three times at an interval of 30 min. The sterilized solutions were packed into 50-ml centrifuge tubes, stored at 4C, and incubated at 37C before use.

From wild-type C57/B16 mice (Huafukang Co., Beijing) aged 5 days old, dermal homogenates were prepared by homogenizing freshly collected hairless mouse PD with isotonic phosphate buffer (pH 7.4) for 20 min in an ice bath to obtain 25% (w/v) tissue suspension. The supernatant was obtained after centrifugation at 4C for 20 min at 10,000g. The DNA content was determined using Hoechst 33258 assay (Beyotime, Beijing). The fluorescence intensity was measured to assess the amount of remaining DNA within the decellularized ECMs and the native tissue using a fluorescence spectrophotometer (Thermo Scientific, Evolution 260 Bio, USA). The GAGs content was estimated via 1,9-dimethylmethylene blue solution staining. The absorbance was measured with microplate reader at wavelength of 492 nm. The standard curve was made using chondroitin sulfate A. The total COL (Collagen) content was determined via hydroxyproline assay. The absorbance of the samples was measured at 550 nm and quantified by referring to a standard curve made with hydroxyproline.

MSCs were bioprinted with matrix materials by using an extrusion-based 3D bioprinter (Regenovo Co., Bio-Architect PRO, Hangzhou). Briefly, 10 ml of gelatin solution (10% w/v) and 5 ml of alginate solution (2% w/v) were warmed under 37C for 20 min, gently mixed as bioink and used within 30 min. MSCs were collected from 100-mm dishes, dispersed into single cells, and 200 l of cell suspension was gently mixed with matrix material under room temperature with cell density 1 million ml1. PD (58 g/ml) was then gently mixed with bioink. Petri dishes at 60 mm were used as collecting plates in the 3D bioprinting process. Within a temperature-controlled chamber of the bioprinter, with temperature set within the gelation region of gelatin, the mixture of MSCs and matrix materials was bioprinted into a cylindrical construct layer by layer. The nozzle-insulation temperature and printing chamber temperature were set at 18 and 10C, respectively; nozzles with an inner diameter of 260 m were chosen for printing. The diameter of the cylindrical construct was 30 mm, with six layers in height. After the temperature-controlled bioprinting process, the printed 3D constructs were immersed in 100-mM calcium chloride (Sigma-Aldrich, USA) for 3 min for cross-linking, then washed with Dulbeccos modified Eagle medium (DMEM) (Gibco, USA) medium for three times. The whole printing process was finished in 10 min. The 3D cross-linked construct was cultured in DMEM in an atmosphere of 5% CO2 at 37C. The culture medium was changed to SG medium [contains 50% DMEM (Gibco, New York, NY) and 50% F12 (Gibco) supplemented with 5% fetal calf serum (Gibco), 1 ml/100 ml penicillin-streptomycin solution, 2 ng/ml liothyronine sodium (Gibco), 0.4 g/ml hydrocortisone succinate (Gibco), 10 ng/ml epidermal growth factor (PeproTech, Rocky Hill, NJ), and 1 ml/100 ml insulin-transferrin-selenium (Gibco)] 2 days later. The cell morphology was examined and recorded under an optical microscope (Olympus, CX40, Japan).

Fluorescent live/dead staining was used to determine cell viability in the 3D cell-loaded constructs according to the manufacturers instructions (Sigma-Aldrich, USA). Briefly, samples were gently washed in PBS three times. An amount of 1 M calcein acetoxymethyl (calcein AM) ester (Sigma-Aldrich, USA) and 2 M propidium iodide (Sigma-Aldrich, USA) was used to stain live cells (green) and dead cells (red) for 15 min while avoiding light. A laser scanning confocal microscopy system (Leica, TCSSP8, Germany) was used for image acquisition.

The cell-printed structure was harvested and fixed with a solution of 4% paraformaldehyde. The structure was embedded in optimal cutting temperature (OCT) compound (Sigma-Aldrich, USA) and sectioned 10-mm thick by using a cryotome (Leica, CM1950, Germany). The sliced samples were washed repeatedly with PBS solution to remove OCT compound and then permeabilized with a solution of 0.1% Triton X-100 (Sigma-Aldrich, USA) in PBS for 5 min. To reduce nonspecific background, sections were treated with 0.2% bovine serum albumin (Sigma-Aldrich, USA) solution in PBS for 20 min. To visualize iSGCs, sections were incubated with primary antibody overnight at 4C for anti-K8 (1:300), anti-K14 (1:300), anti-K18 (1:300), anti-K19 (1:300), anti-ATP1a1 (1:300), anti-Ki67 (1:300), antiN-cadherin (1:300), antiE-cadherin (1:300), anti-CTHRC1 (1:300), or anti-TSP1 (1:300; all Abcam, UK) and then incubated with secondary antibody for 2 hours at room temperature: Alexa Fluor 594 goat anti-rabbit (1:300), fluorescein isothiocyanate (FITC) goat anti-rabbit (1:300), FITC goat anti-mouse (1:300), or Alexa Fluor 594 goat anti-mouse (1:300; all Invitrogen, CA). Sections were also stained with 4,6-diamidino-2-phenylindole (Beyotime, Beijing) for 15 min. Stained samples were visualized, and images were captured under a confocal microscope.

To harvest the cells in the construct, the 3D constructs were dissolved by adding 55 mM sodium citrate and 20 mM EDTA (Sigma-Aldrich, USA) in 150 mM sodium chloride (Sigma-Aldrich, USA) for 5 min while gently shaking the petri dish for better dissolving. After transfer to 15-ml centrifuge tubes, the cell suspensions were centrifuged at 200 rpm for 3 min, and the supernatant liquid was removed to harvest cells for further analysis.

Total RNA was isolated from cells by using TRIzol reagent (Invitrogen, USA) following the manufacturers protocol. RNA concentration was measured by using a NanoPhotometer (Implen GmbH, P-330-31, Germany). Reverse transcription involved use of a complementary DNA synthesis kit (Takara, China). Gene expression was analyzed quantitatively by using SYBR green with the 7500 Real-Time PCR System (Takara, China). The primers and probes for genes were designed on the basis of published gene sequences (table S1) (National Center for Biotechnology Information and PubMed). The expression of each gene was normalized to that for glyceraldehyde-3-phosphate dehydrogenase and analyzed by the 2-CT method. Each sample was assessed in triplicate.

The culture medium was changed to SG medium with 2 mM CaCl2 for at least 24 hours, and cells were loaded with fluo-3/AM (Invitrogen, CA) at a final concentration of 5 M for 30 min at room temperature. After three washes with calcium-free PBS, 10 M acetylcholine (Sigma-Aldrich, USA) was added to cells. The change in the Fluo 3 fluorescent signal was recorded under a laser scanning confocal microscopy.

Cell proliferation was evaluated through CCK-8 (Cell counting kit-8) assay. Briefly, cells were seeded in 96-well plates at the appropriate concentration and cultured at 37C in an incubator for 4 hours. When cells were adhered, 10 l of CCK-8 working buffer was added into the 96-well plates and incubated at 37C for 1 hour. Absorbance at 450 nm was measured with a microplate reader (Tecan, SPARK 10M, Austria).

Proteomics of mouse PD and DD involved use of isobaric tags for relative and absolute quantification (iTRAQ) in BGI Company, with differentially expressed proteins detected in PD versus DD. Twofold greater difference in expression was considered significant for further study.

Tissues were grinded and lysed in radioimmunoprecipitation assay buffer (Beyotime, Nanjing). Proteins were separated by 12% SDSpolyacrylamide gel electrophoresis and transferred to a methanol-activated polyvinylidene difluoride membrane (GE Healthcare, USA). The membrane was blocked for 1 hour in PBS with Tween 20 containing 5% bovine serum albumin (Sigma-Aldrich, USA) and probed with the antibodies anti-CTHRC1 (1:1000) and anti-TSP1 (1:1000; both Abcam, UK) overnight at 4C. After 2 hours of incubation with goat anti-rabbit horseradish peroxidaseconjugated secondary antibody (Santa Cruz Biotechnology, CA), the protein bands were detected by using luminal reagent (GE Healthcare, ImageQuant LAS 4000, USA).

Total RNA was prepared with TRIzol (Invitrogen), and RNA sequencing was performed using HiSeq 2500 (Illumina). Genes with false discovery rate < 0.05, fold difference > 2.0, and mean log intensity > 2.0 were considered to be significant.

CAPE or Snpp was gently mixed with bioink at a concentration of 10 M. Physiological concentration of CTHRC1 was measured by enzyme linked immunosorbent assay (ELISA) (80 ng/ml), and then recombinant CTHRC1 or CTHRC1 antibody was added into the bioink at a concentration of 0.4 g/ml. The effect of inhibitor and activator was estimated by qRT-PCR or ELISA.

Mice were anesthetized with pentobarbital (100 mg/kg) and received subcutaneous buprenorphine (0.1 mg/kg) preoperatively. Full-thickness scald injuries were created on paw pads with soldering station (Weller, WSD81, Germany). Mice recovered in clean cages with paper bedding to prevent irritation or infection. Mice were monitored daily and euthanized at 30 days after wounding. Mice were maintained in an Association for Assessment and Accreditation of Laboratory Animal Careaccredited animal facility, and procedures were performed with Institutional Animal Care and Use Committeeapproved protocols.

MSCs in 3D-printed constructs with PD were cultured with DMEM for 2 days and then replaced with SG medium. The SG medium was changed every 2 days, and cells were harvested on day 12. The K18+ iSGCs were sorting through flow cytometry and injected into the paw pads (1 106 cells/50 l) of the mouse burn model by using Microliter syringes (Hamilton, 7655-01, USA). Then, mice were euthanized after 14 days; feet were excised and fixed with 10% formalin (Sigma-Aldrich, USA) overnight for paraffin sections and immunohistological analysis.

The foot pads of anesthetized treated mice were first painted with 2% (w/v) iodine/ethanol solution then with starch/castor oil solution (1 g/ml) (Sigma-Aldrich, USA). After drying, 50 l of 100 M acetylcholine (Sigma-Aldrich, USA) was injected subcutaneously into paws of mice. Pictures of the mouse foot pads were taken after 5, 10, and 15 min.

All data were presented as means SEM. Statistical analyses were performed using GraphPad Prism7 statistical software (GraphPad, USA). Significant differences were calculated by analysis of variance (ANOVA), followed by the Bonferroni test when performing multiple comparisons between groups. P < 0.05 was considered as a statistically significant difference.

Supplementary material for this article is available at http://advances.sciencemag.org/cgi/content/full/6/10/eaaz1094/DC1

Fig. S1. Biocompatibility of 3D-bioprinted construct and cellular morphology in 2D monolayer culture.

Fig. S2. Expression of SG-specific and secretion-related markers in MSCs and SG cells in vitro.

Fig. S3. Transcriptional and translational expression of epithelial and mesenchymal markers in 3D-bioprinted cells with and without PD.

Fig. S4. Expression of N- and E-cadherin in MSCs and SG cells in 2D monolayer culture.

Fig. S5. Proteomic microarray assay of differential gene expression between PD and DD ECM in postnatal mice.

Fig. S6. GO term analysis of differentially expressed pathways.

Fig. S7. Heat maps illustrating differential expression of genes implicated in ECM organization, cell division, and gland and branch morphogenesis.

Fig. S8. The expression of Hmox1 and the concentration of CTHRC1 on treatment and the related effects on cell proliferation.

Fig. S9. The expression of K8 and K18 with Hmox1 and CTHRC1 regulation.

Table S1. Primers for qRT-PCR of all the genes.

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.

Acknowledgments: Funding: This study was supported in part by the National Nature Science Foundation of China (81571909, 81701906, 81830064, and 81721092), the National Key Research Development Plan (2017YFC1103300), Military Logistics Research Key Project (AWS17J005), and Fostering Funds of Chinese PLA General Hospital for National Distinguished Young Scholar Science Fund (2017-JQPY-002). Author contributions: B.Y. and S.H. were responsible for the design and primary technical process, conducted the experiments, collected and analyzed data, and wrote the manuscript. Y.W. and R.W. helped perform the main experiments. Y.Z. and T.H. participated in the 3D printing. W.S. and Z.L. participated in cell experiments and postexamination. S.H. and X.F. collectively oversaw the collection of data and data interpretation and revised the manuscript. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

Read the original here:
Biochemical and structural cues of 3D-printed matrix synergistically direct MSC differentiation for functional sweat gland regeneration - Science...

UC scientist finds new solution to fight superbug infections – WCPO Cincinnati

CINCINNATI It only took years of studying, getting his PhD and completing post-doc positions at two universities for Daniel Hassett to land a job that eventually led him to discover a drug that can fight superbug infections resistant to antibiotics.

No, it's not a cure for coronavirus, but it's pretty darn cool. At least, that's what Hassett, a professor in the UC Department of Molecular Genetics, Biochemistry and Microbiology, will tell you.

Its actually beyond a big deal -- Its huge, Hassett said while standing in the laboratory where he made this discovery. The real plus of it is that it not only kills all of bacteria, but it kills the ones that are the most antibiotic-resistant bacteria.

Paola Suro

The bacteria he has been fighting makes about 2.8 million people in the United States sick every year and kills more than 35,000 people, according to the Centers for Disease Control and Prevention.

In very, very severe infections where the bugs are resistant to everything, its virtually impossible for them to become resistant to my drug, he said. Its not only anti-microbial, it has powerful wound-healing capacity as well.

Paola Suro

The invention called AB569 is composed of ingredients pacified nitrite and ethylenediaminetetraacetic acid and kills one of the most serious bacterium (Pseudomonas aeruginosa) that is resistant to several drugs and virulence.

Even if it positively affects one patient with a certain anomaly, just one, its a good thing, Hassett said. But we think its going to be pretty ubiquitous as far as this treatment goes.

Paola Suro

At first, researchers found AB569 could potentially treat antibiotic-resistant organisms that cause pulmonary infections in people with cystic fibrosis and chronic obstructive pulmonary disease, among others. Since then, Hassett said he has found it could do more than that, including treat urinary tract disorders, heal wounds, and even treat diabetes.

AB569 kills these pathogenic bacteria by targeting their DNA, RNA and protein biosynthesis as well as energy and iron metabolism at concentrations that do not harm human cells, he explained to UC Health researchers. These were tested in laboratory mice and humanized cells. Our data implicate that AB569 is a safe and effective means that could be applied to eradicate these superbugs.

Pseudomonas aeruginosa was placed in the lungs of lab mice for five days. It's considered one of the six ESKAPE pathogens, which, according to Hassett, are among the most resistant and deadly to humans. It includes Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. These pathogens can result in infections and illnesses like pneumonia and MRSA.

Paola Suro

His discovery was patented in March 2018, but now he is working on getting more funding and support to push this discovery further.

Go here to read the rest:
UC scientist finds new solution to fight superbug infections - WCPO Cincinnati

Itaconic Acid (IA) Market 2020 Outlook and Forecasts 2026 by Top Manufacturers, Production, Consumption, Trade Statistics, and Growth Analysis – News…

The Itaconic Acid (IA) Market report enlightens its readers about its products, applications, and specifications. The research enlists key companies operating in the market and also highlights the roadmap adopted by the companies to consolidate their position in the market. By extensive usage of SWOT analysis and Porters five force analysis tools, the strengths, weaknesses, opportunities, and combination of key companies are comprehensively deduced and referenced in the report. Every single leading player in this global market is profiled with their related details such as product types, business overview, sales, manufacturing base, applications, and other specifications.

Major Market Players Covered In This Report: Kehai Biochemistry, Guoguang Biochemistry, Huaming Biochemistry, Alpha Chemika, Zhongshun Science & Technology

Click Here To Access The Sample Report: https://www.acquiremarketresearch.com/sample-request/341505/

Itaconic Acid (IA) Market has exhibited continuous growth in the recent past and is projected to grow even more throughout the forecast. The analysis presents an exhaustive assessment of the market and comprises Future trends, Current Growth Factors, attentive opinions, facts, historical information, in addition to statistically supported and trade validated market information.

The Global Itaconic Acid (IA) Market Can Be Segmented As The key product type of Itaconic Acid (IA) market are: Synthesis, Fermentation

Itaconic Acid (IA) Market Outlook by Applications: Plasticizer, Lubricating Oil Additive

To Get This Report At Beneficial Rates: https://www.acquiremarketresearch.com/discount-request/341505/

The Itaconic Acid (IA) market comprising of well-established international vendors is giving heavy competition to new players in the market as they struggle with technological development, reliability and quality problems the analysis report examines the expansion, market size, key segments, trade share, application, and key drivers.

Itaconic Acid (IA) Market Research Methodology: This study estimates a detailed qualitative and quantitative analysis of the Itaconic Acid (IA) market. Primary sources, such as experts from related industries and suppliers of Itaconic Acid (IA) were interviewed to obtain and verify critical information and assess business prospects of the Itaconic Acid (IA) market.

Key players within the Itaconic Acid (IA) market are identified through secondary analysis, and their market shares are determined through primary and secondary analysis. The report encloses a basic summary of the trade lifecycle, definitions, classifications, applications, and trade chain structure. Each of these factors can facilitate leading players to perceive the scope of the Market, what unique characteristics it offers and the manner in which it will fulfill a customers need.

By Company Profile, Product Image and Specification, Product Application Analysis, Production Capability, Price Cost, Production Value, Contact Data are included in this research report.

What Itaconic Acid (IA) Market report offers: Itaconic Acid (IA) Market share assessments for the regional and country-level segmentsMarket share analysis of the highest trade playersItaconic Acid (IA) Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and Recommendations)Strategic recommendations on key business segments

The Report Answers Following Questions: Over successive few years, which Itaconic Acid (IA) application segment can perform well?Within which market, the businesses ought to establish a presence?Which product segments are exhibiting growth?What are the market restraints which are likely to impede the growth rate?However, market share changes their values by completely different producing brands?

To Know More About The Assumptions in This Market Report: https://www.acquiremarketresearch.com/industry-reports/itaconic-acid-ia-market/341505/

The report entails detailed profiling of each company, and information on capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments, are also included within the scope of the report. In the end, the Itaconic Acid (IA) Market Report delivers a conclusion which includes Breakdown and Data Triangulation, Consumer Needs/Customer Preference Change, Research Findings, Market Size Estimation, Data Source. These factors are expected to augment the overall business growth.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like Asia, United States, Europe.

About us:

Acquire Market Research is a market research-based company empowering companies with data-driven insights. We provide Market Research Reports with accurate and well-informed data, Real-Time with Real Application. A good research methodology proves to be powerful and simplified information that applied right from day-to-day lives to complex decisions helps us navigate through with vision, purpose and well-armed strategies. At Acquire Market Research, we constantly strive for innovation in the techniques and the quality of analysis that goes into our reports.

Contact Us:

Sally Mach555 Madison Avenue,5th Floor, Manhattan,New York, 10022 USAPhone No.: +1 (800) 663-5579Email ID: [emailprotected]

Read this article:
Itaconic Acid (IA) Market 2020 Outlook and Forecasts 2026 by Top Manufacturers, Production, Consumption, Trade Statistics, and Growth Analysis - News...